

The Blood-Brain Barrier in Epilepsy

Björn Bauer^{1,2}, Juli Schlichtiger³, Anton Pekcec⁴ and Anika M.S. Hartz^{1,2}

¹*University of Minnesota, College of Pharmacy*

²*Brain Barriers Research Center, University of Minnesota, College of Pharmacy*

³*Ludwig-Maximilians University, Department of Nuclear Medicine, Munich*

⁴*Massachusetts General Hospital, Neuroprotection Research Laboratory*

^{1,2,4}*USA*

³*Germany*

1. Introduction

The blood-brain barrier is altered in epilepsy. This includes altered expression of transporters and metabolic enzymes as well as barrier leakage that have been linked to antiepileptic drug resistance and seizure genesis, respectively. Here we highlight current understanding of these pathological changes. Three critical components of barrier function - 1) tight junctions, 2) metabolising enzymes and 3) transporter proteins - are introduced and we describe how they are changed in epilepsy and affected by epilepsy treatment. Recent efforts in blood-brain barrier research to overcome drug-resistant epilepsy are also discussed.

2. The blood-brain barrier

The History of Blood-Brain Barrier Discovery. First experiments contributing to the discovery of the blood-brain barrier were performed by Paul Ehrlich in 1885 (Figure 1). Ehrlich observed that water-soluble “vital dyes” injected into the blood of rats did not stain the brain (Ehrlich, 1885). In 1900, Lewandowsky made similar observations and coined the term “blood-brain barrier” (“Bluthirnschranke”) to explain this phenomenon (Lewandowsky, 1900). Ehrlich’s student, Edwin Goldmann, injected the same dyes Ehrlich had used into the subarachnoid space, and found the opposite: intense staining of the brain but no staining of peripheral tissues (Goldmann, 1909; 1913). Goldmann concluded that a barrier had to exist between the brain and the periphery, thus the concept of a vascular barrier was born. In 1923, Spatz postulated that the brain capillary endothelium had to be the structure responsible for barrier function, which initiated a debate that lasted for decades (Spatz, 1933). It was Reese and Karnovsky, and Brightman and Reese who solved the mystery of the blood-brain barrier in the late 1960s. Using electron microscopy, they discovered that tight junctions connect adjacent capillary endothelial cells and seal the intercellular space (Brightman & Reese, 1969; Reese & Karnovsky, 1967). With this, the molecular structure responsible for barrier function was identified and the barrier was localized to the brain capillary endothelium.




Fig. 1. Evolution of Blood-Brain Barrier Methodology/History

The History of the Blood-Brain Barrier in Epilepsy. In the 1930s, Aird and Cobb discovered that brain uptake of “vital dyes” was increased in epileptic mice. Based on their observation, they suggested that the brain vasculature may be a barrier between the central nervous system (CNS) and the periphery and that altered brain vascular permeability may be a factor contributing to epilepsy (Aird, 1939; Cobb et al., 1938). In the mid 1950s, Bercel used diuretics in patients to increase brain uptake of antiepileptic drugs (AEDs (Bercel, 1955)). Co-administration with diuretics reduced AED doses below toxic levels in ten of ten patients and in seven of these ten patients seizure control was improved (Bercel, 1955). Nemeroff and Crisley made a critical discovery in 1975 when they found that glutamate is involved in seizure induction and increases cerebrovascular permeability in rats (Nemeroff & Crisley, 1975). Further, blood-brain barrier dysfunction was shown to go along with an increase in blood pressure and cerebral vasodilation during seizures (Bolwig et al., 1977; Petito et al., 1977). In 1989, Clarke and Gabrielsen demonstrated seizure-induced blood-brain barrier leakage in humans using computed tomography (Clarke & Gabrielsen, 1989). In 1995, Tishler et al. made the observation that mRNA of *MDR1* (*ABCB1*), the gene encoding the efflux transporter P-glycoprotein (P-gp) is increased at the blood-brain barrier of patients with drug-resistant epilepsy (Tishler et al., 1995). This was a critical finding because P-gp acts as a “gatekeeper” that limits therapeutic drugs from crossing the blood-brain barrier and from entering the brain (Miller et al., 2008). Research in this field initially focused on P-gp, but other transporters such as multidrug resistance proteins (MRPs) and breast cancer resistance protein (BCRP) are also increased in epilepsy animal models or patients (Awasthi et al., 2005; Dombrowski et al., 2001; Sisodiya et al., 2006; Van Vliet et al., 2005).

Today, the role of some of these transporters in epilepsy is still unclear. It has been discussed that P-gp could be involved in seizure generation (Marchi et al., 2004) and that multiple transporters may act in concert to limit brain uptake of a broad range of AEDs (Lazarowski et al., 2007). Recent studies show that AED-metabolizing enzymes such as cytochromes (CYP) 3A4, 2C8, and glutathione sulfotransferase (GST) μ and π are also upregulated in the brain of epileptic patients forming a metabolic barrier that contributes to AED resistance (Ghosh et al., 2010; Shang et al., 2008; Ueda et al., 2007).

2.1 Blood-brain barrier anatomy

Numbers and Facts. The blood-brain barrier is a network of brain capillaries (microvessels). With a diameter of 3-7 μ m, brain capillaries are the smallest vessels of the vascular system (Figure 2A) (Rodriguez-Baeza et al., 2003). The microvasculature in the human brain is comprised of about 100 billion capillaries forming a highly branched vascular network

(Zlokovic & Apuzzo, 1998). Due to the high capillary density in the brain, capillaries are about 40 μm apart from each other, a distance short enough for small molecules to diffuse within 1 second (Rodriguez-Baeza et al., 2003). This ensures that every neuron (about 100 billion in human brain) is in contact with and perfused by its own capillary, which allows efficient nutrient and oxygen supply. Despite the huge number of 100 billion brain capillaries, the total capillary lumen occupies only about 1% of total brain volume, or about 12-15 ml in an adult human brain of about 1,400 ml (Pardridge, 2003b). Thus, at any given time, about 8-10% (about 10 ml) of total cerebral blood (about 150 ml) is in the lumen of brain capillaries. Not taking the capillary lumen into account, it is estimated that the brain capillary endothelium occupies only about 0.1% of total brain volume (\sim 1-1.5 ml) (Pardridge, 2003b). Lastly, the total length of the capillary network is about 600-650 km in an adult human brain with a total surface area of about 20 m^2 . This makes the blood-brain barrier the third largest surface area for drug exchange after intestine and lung (Pardridge, 2003a).




Fig. 2. (A). DIC image of isolated brain capillary. (B) Neurovascular unit.

Morphology and Anatomy. Brain capillaries are the next higher level of organisation from endothelial cells that are the smallest anatomical unit of microvessels. Brain capillary endothelial cells are flat, thin, spindle-shaped, polarized cells. Their apical membrane faces the blood (luminal), and their basolateral membrane faces the brain parenchyma (abluminal; (Betz et al., 1980)). It is through the basement membrane that brain capillary endothelial cells are in contact with pericytes, astrocytes, and neurons (Figure 2B; (Goldstein & Betz, 1983)). This 4-cell structure is referred to as “*Neurovascular Unit*” and is responsible for maintaining and regulating blood flow, and for controlling barrier function (Begley, 2004).

One fundamental characteristic of endothelial barrier function is a complex, multi-protein structure called a *tight junction*, which is unique in the vascular system (Nagy et al., 1984). Brain capillary endothelial cells also lack intercellular clefts and have low pinocytotic activity, which limits solute exchange between blood and brain. Lastly, to meet the large energy demand of ATP-consuming processes like metabolism and active efflux transport, brain capillary endothelial cells possess a large number of mitochondria (Goldstein & Betz, 1983).

2.2 Blood-brain barrier physiology

Blood-brain barrier functions include CNS protection, and regulation and maintenance of CNS homeostasis. Three components determine barrier function: 1. *Tight Junctions*, 2.

Transporters and *3. Metabolising Enzymes*. The following paragraphs describe these components in more detail.

1. Tight Junctions

Tight junctions are cell-cell contacts that seal the intercellular space between adjacent endothelial cells, thereby creating a non-fenestrated endothelium and limiting hydrophilic molecules from paracellular diffusion (Nag, 2003). Tight junctions are multi-protein complexes composed of transmembrane proteins like occludins, claudins, e-cadherins and junctional adhesion molecules as well as adaptor and regulatory proteins (Matter & Balda, 2003a; Vorbrodt & Dobrogowska, 2003). Adaptor proteins include zonula occludens proteins, cingulin, catenin and membrane-associated guanylate kinase inverted proteins that connect junctional transmembrane proteins with cytoskeletal actin filaments (Matter & Balda, 2003b). Regulatory proteins include G proteins, atypical protein kinase C isoforms, and symplektin that are involved in signalling (Matter & Balda, 2003b; Wolburg & Lippoldt, 2002). Together, tight junctions guarantee a tight barrier, and thus, protection of the CNS (Kniesel & Wolburg, 2000). However, under pathological conditions such as epilepsy, tight junctions can be dysfunctional or disrupted, leading to barrier leakage, impaired neuronal function, and brain damage (Huber et al., 2001).

2. Metabolic Enzymes

The concept of a "metabolic barrier" is widely accepted but little information is available on metabolising enzymes at the blood-brain barrier. Early studies focused on phase I enzymes in whole brain tissue but later studies differentiated between different brain cell types. Walther et al. showed that CYP P450 enzymes are located in the inner mitochondrial membrane of neurons and glia from rat, guinea pig, rabbit, and pig brain. This is in contrast to liver, where most CYP isoforms are located at the endoplasmic reticulum (Walther et al., 1986). Consistent with this, Ghersi-Egea et al. found CYP P450 protein expression in mitochondria from rat brain tissue (Ghersi-Egea et al., 1987), and demonstrated CYP activity in various brain regions and isolated human microvessels. They found low 1-naphthol-UDP-glucuronosyltransferase and NADPH-CYP P450 reductase activity, and high GST and epoxide hydrolase activity (Ghersi-Egea et al., 1993). The same group also found Cyp P450 activity in rat brain microvessels (Ghersi-Egea et al., 1994).

Dauchy et al. used isolated microvessels from resected human brain and found mRNA expression of CYP1A1, 1B1, 2B6, 2C8, 2D6, 2E1, 2J2, 2R1, 2S1, and 2U1, and detected CYP1B1 by Western blotting (Dauchy et al., 2008). Immunohistological studies by Rieder et al. confirmed localisation of CYP1B1 in human brain capillaries (Rieder et al., 2000). In a follow up study, Dauchy et al. showed CYP2U1 and CYP2S1 mRNA expression in the human cerebral microvascular endothelial cell line hCMEC/D3 (Dauchy et al., 2009). CYPs with low mRNA expression included CYP2R1, 2B6, 2E1, 1A1, 2D6, 2C18, 1B1, 2J2, 1A2 and 2C8. Except for CYP2C18, all CYP genes found in hCMEC/D3 cells were also detected in isolated human brain microvessels. A novel CYP P450, Cyp4x1, was identified in 2006 by Al-Aznizy et al. in mouse brain (Al-Anizy et al., 2006). Immunohistochemical staining showed strong Cyp4x1 protein expression in neurons, choroid plexus epithelial cells, and brain microvessel endothelial cells. In 2010, mRNA and protein expression of CYP3A4, the most prominent enzyme involved in xenobiotic metabolism in the liver, was found by Ghosh et al. in human brain endothelial cells (Ghosh et al., 2010).

While most blood-brain barrier enzymes have been detected at the mRNA level, protein expression and activity of only few enzymes have been demonstrated. These include

gamma-glutamyl transpeptidase (Beuckmann et al., 1995), alkaline phosphatase (Beuckmann et al., 1995), aromatic L-amino acid decarboxylase (Betz et al., 1980; Matter & Balda, 2003b), the phase I metabolising enzymes CYP1A1 (Filbrandt et al., 2004), CYP1B1 (Filbrandt et al., 2004), CYP3A4 (Ghosh et al., 2010; Ghosh et al., 2011), and Cyp4x1 (Al-Anizy et al., 2006), NADPH-CYP P450 reductase (Chat et al., 1998; Ghersi-Egea et al., 1988; Minn et al., 1991; Ravindranath et al., 1990), epoxide hydrolase (Ghersi-Egea et al., 1988; Minn et al., 1991), and the phase II enzymes, 1-naphthol-UDP-glucuronosyltransferase (Ghersi-Egea et al., 1988) and GST μ (Shang et al., 2008), and GST π (Bauer et al., 2008; Shang et al., 2008).

The presence of these enzymes in the brain microvasculature indicates the existence of a metabolic barrier. However, more studies are needed to better define the role metabolising enzymes play at the blood-brain barrier under physiological and pathophysiological conditions and whether these enzymes can indeed limit AED delivery to the brain.

3. Transporters

The blood-brain barrier is an active, dynamic and selective interface that responds to signals from both the periphery and brain. Key components of barrier function include influx and efflux transporters that are responsible for brain homeostasis, nutrient supply, and protection of the brain from endogenous and exogenous toxins.

Influx transporters that maintain CNS homeostasis and nutrient supply include A-and N-system amino acid transporters (Betz et al., 1980; O'kane & Hawkins, 2003), excitatory amino acid carriers 1, 2, and 3 (O'kane & Hawkins, 2003; O'kane et al., 1999), alanine-serine/cysteine/threonine (ASCT) transporters for neutral amino acids (Boado et al., 2004; Tayarani et al., 1987), glucose transporters GLUT1 and GLUT3/14 (Pardridge, 1991; Simpson et al., 2007), monocarboxylate transporters MCT1 and MCT8 (Braun et al., 2011; Ito et al., 2011; Simpson et al., 2007), and the equilibrative nucleoside transporter ENT1 (Kitano et al., 2002), as well as Na⁺-K⁺-ATPase (Betz et al., 1980). These transporters belong to the solute carrier (SLC) superfamily. Prominent SLC transporters that have been detected at the blood-brain barrier also include the organic anion transporter Oat3, organic anion transporting polypeptides Oatp1a4, 1b1, 1c1, 2b1, 14, and organic cation transporters OCT1, OCT2 (Ito et al., 2011; Lin et al., 2010). Of these SLCs, Oat3, Oatps, and Octs are involved in drug transport. However, it is currently not known if these SLC transporters can handle AEDs.

An interesting blood-brain barrier transporter is the large neutral amino acid transporter LAT that transports the amino acids valine, leucine, isoleucine, tryptophan, and tyrosine. LAT1 mediates brain uptake of L-DOPA that is used in Parkinson's disease (Del Amo et al., 2008). LAT1 has also been reported to transport the AEDs gabapentin and pregabalin across the blood-brain barrier into the brain (Del Amo et al., 2008; Liu et al., 2008; Su et al., 1995). Whether LATs are affected in epilepsy is unknown.

In total, 21 transporters have been detected at the protein level in brain capillaries and brain capillary endothelial cells from various species by immunohistochemistry, Western blotting, or quantitative LC/MS/MS (Kamiie et al., 2008; Neuwelt et al., 2011). Seven of these transporters belong to the ABC (ATP-binding cassette) transporter family and include P-glycoprotein (P-gp, *MDR1*, *ABCB1*), the multidrug resistance proteins 1, 2, 3, 4, and 5 (MRPs, *ABCC1-5*) and breast cancer resistance protein (BCRP, *ABCG2*). These transporters are ATP-driven and mainly located at the luminal membrane of the brain capillary endothelium (Mrp1 and Mrp4 are also in the abluminal membrane). This "first line of defence" protects the brain from neurotoxicants and limits CNS drugs from entering the brain, and thus, is an obstacle for CNS pharmacotherapy.

Together, transporters ensure proper CNS nutrient supply and mediate efflux of metabolic wastes from the brain, thus, helping maintain CNS homeostasis. The following section describes the role of transporters, metabolic enzymes, and barrier leakage in epilepsy.

3. Blood-brain barrier function in epilepsy

Epilepsy affects more than 60 million people worldwide. The majority of patients respond to treatment with AEDs, but up to 40% of patients are drug-resistant (Kwan & Brodie, 2003; Loscher & Potschka, 2005). Patients with AED resistance suffer from uncontrolled seizures, which elevates their risk of brain damage and mortality (Sperling et al., 1999). These patients experience a low quality of life and, despite advances in pharmacotherapy and neurosurgery, drug-resistant epilepsy remains a major clinical problem (Devinsky, 1999). Evidence indicates that the blood-brain barrier is altered in patients with epilepsy. Changes in the brain capillary endothelium include upregulation of efflux transporters and metabolic enzymes as well as barrier leakage that have been linked to AED resistance and seizure genesis (Bauer et al., 2008; Ghosh et al., 2010; Marchi et al., 2007). The following section describes the role of transporters, metabolic enzymes, and barrier leakage in epilepsy.

3.1 Transporters in epilepsy

One factor underlying AED resistance is, at least in part, seizure-induced over-expression of drug efflux transporters at the blood-brain barrier (Bauer et al., 2008). Some of these transporters, such as P-gp, Mrp2, and BCRP have been implicated with AED resistance. The first evidence for involvement of efflux transporters in epilepsy goes back to studies by Tishler and co-workers in 1995. These researchers observed increased P-gp mRNA in the brain and protein expression in the capillary endothelium of patients with drug-resistant epilepsy (Tishler et al., 1995). The findings by Tishler et al. were confirmed by other groups (Dombrowski et al., 2001; Lazarowski et al., 1999; Sisodiya et al., 2002) and it was suggested that this phenomenon could prevent AEDs from entering the brain and cause AED resistance. However, studies in cell lines of non-brain endothelial origin showed that some AEDs such as vigabatrin, gabapentin, phenobarbitone, lamotrigine, carbamazepine, and phenytoin are not, or are only weak, P-gp substrates, questioning whether P-gp could be the primary reason for AED resistance (Crowe & Teoh, 2006; Maines et al., 2005; Owen et al., 2001; Weiss et al., 2003). In contrast, Cucullo et al., compared phenytoin permeation in brain capillary endothelial cells from drug-resistant epileptic human brain tissue with that of commercially available human brain microvascular endothelial cells (Cucullo et al., 2007). They demonstrated that phenytoin permeation was 10-fold lower in endothelial cells from AED-resistant patients compared to purchased human endothelial cells. Although this comparison is flawed, inhibiting P-gp increased phenytoin permeation in the AED-resistant cells. Moreover, recent *in vivo* data, including our own studies, demonstrate that P-gp does limit AEDs from entering the brain (Brandt et al., 2006; Liu et al., 2007; Van Vliet et al., 2007). Using a drug-resistant epilepsy rat model, Potschka et al. showed that animals not responding to phenytoin exhibited 2-fold higher P-gp expression levels in brain capillaries compared to animals responding to treatment (Potschka et al., 2004). van Vliet et al. demonstrated that inhibiting P-gp counteracted phenytoin resistance, which reduced seizure occurrence in rats (Van Vliet et al., 2006). Marchi et al. supported these findings showing that patients with high blood-brain barrier P-gp expression had low brain levels of

oxcarbazepine (Marchi et al., 2005). These studies demonstrate that, in drug-resistant epilepsy, certain, but not all AEDs have restricted access to the brain due to increased blood-brain barrier P-gp, and that modulation of P-gp can enhance brain distribution of some AEDs such as phenytoin (Potschka & Loscher, 2001; Van Vliet et al., 2006; Van Vliet et al., 2007).

In addition to P-gp, data indicate that BCRP plays a significant role in drug efflux at the blood-brain barrier. Recent studies show that both transporters, P-gp and BCRP, "team up" and work together to limit chemotherapeutic drugs from permeating across the blood-brain barrier and penetrating into the brain (Chen et al., 2009; De Vries et al., 2007). However, little information is available on the extent to which BCRP contributes to AED resistance and if P-gp and BCRP work in concert in AED efflux from the brain. Some studies found no upregulation of BCRP in human epileptogenic brain tissue and no evidence for BCRP-mediated AED transport *in vitro* (Cerveny et al., 2006; Sisodiya et al., 2003), but other studies reported upregulation of BCRP expression in the microvasculature of epileptogenic brain tumors (Aronica et al., 2005; Vogelgesang et al., 2004) and in chronic epilepsy animal models (Van Vliet et al., 2005). More studies are needed to unequivocally clarify the role of BCRP, especially in conjunction with P-gp, in AED-resistant epilepsy.

Only little information is available on the multidrug resistance proteins (Mrps) in epilepsy. van Vliet et al. used the pilocarpine status epilepticus model in rats and found by immunohistochemistry and Western blotting that Mrp1 and Mrp2 protein expression was upregulated in astrocytes within several limbic structures including the hippocampus (Van Vliet et al., 2005). These findings were confirmed by Hoffmann et al., who also demonstrated Mrp2 upregulation in brain capillaries by immunohistochemistry following pilocarpine-induced status epilepticus (Hoffmann et al., 2006). In control rats, Mrp2 was barely detectable in the brain capillary endothelium, but in status epilepticus rats, Mrp2 staining was evident in brain capillary endothelial cells. MRP2 has also been found to be over-expressed in sclerotic hippocampal tissue of AED-resistant patients with mesial temporal lobe epilepsy (Aronica et al., 2004). In the same patient population, MRP1 expression was upregulated in glial endfoot processes around cerebral blood vessels. Observations of chronic epileptic rats showed that protein levels of Mrp1 and Mrp2 were also upregulated in blood vessels and this over-expression correlated with seizure frequency and reduced brain uptake of phenytoin (Van Vliet et al., 2005). However, phenytoin brain uptake was enhanced by the MRP inhibitor probenecid. While upregulation of mRNA was observed for Mrp1, 5, and 6, increased protein expression was only found for MRP1 and 2 in isolated capillary endothelial cells from patients with drug-resistant epilepsy (Dombrowski et al., 2001; Kubota et al., 2006). A time-course study revealed that 6-24 h after onset of a pilocarpine-induced status epilepticus in rats, mRNA of P-gp, Mrp1, and Mrp5 was decreased in hippocampus, amygdala, and the piriform cortex. This initial decrease in mRNA levels was followed by a 24h period of normal mRNA expression and then increased mRNA levels about 4 days after status epilepticus (Kuteykin-Teplyakov et al., 2009). These findings are in contrast to an earlier study where P-gp mRNA levels in mouse hippocampus were increased by 85% 3-24 h after kainic acid-induced limbic seizures, but returned to control levels after 72 h (Rizzi et al., 2002). Treatment with AEDs for 7 days did not change P-gp mRNA expression (Rizzi et al., 2002). In the same study, the authors also used rats with spontaneous recurrent seizures 3 months after electrically induced status epilepticus. P-gp mRNA levels were increased 1.8- and 5-fold in the hippocampus and entorhinal cortex,

respectively. Thus, changes in P-gp mRNA levels occur after both acute and chronic epileptic activity. The same authors (Rizzi et al., 2002) also used microdialysis and demonstrated that AED brain levels were significantly reduced. While a direct connection between blood-brain barrier P-gp levels and AED brain levels was not shown, it was concluded that seizure-induced changes in P-gp could contribute to AED resistance in epilepsy. Note that none of these studies provided data on transporter protein expression or activity.

3.1.1 Transporter inhibition

The discovery that drug efflux transporters are upregulated at the blood-brain barrier in AED-resistant patients suggested that transporter inhibition could overcome AED resistance in epilepsy. This notion was encouraged by studies that showed enhanced brain uptake of AEDs when co-administered with transporter inhibitors. Using verapamil and probenecid, Potschka et al. used microdialysis and demonstrated in healthy rats that P-gp and MRP limit carbamazepine brain uptake (Potschka & Loscher, 2001). A follow-up study showed that administration of the metabolic inhibitor sodium cyanide and the P-gp inhibitors verapamil and PSC833 into the frontal cortex significantly increased extracellular fluid concentrations of phenytoin. This indicated that P-gp limits phenytoin distribution into the brain under physiological conditions (Potschka & Loscher, 2001). Similar observations were made with phenobarbital, lamotrigine, and felbamate (Potschka et al., 2002). Verapamil has also been used in case studies with AED-resistant patients (Iannetti et al., 2005; Summers et al., 2004). For example, the status epilepticus in an 11-year old boy who was first unresponsive to conventional AEDs disappeared after administration of verapamil i.v. (Iannetti et al., 2005). However, this anticonvulsive response could have been due to verapamil directly blocking neuronal calcium channels instead of inhibiting P-gp at the blood-brain barrier.

In 2005, tariquidar (XR9576), a non-competitive P-gp inhibitor was first used to block P-gp function. (Martin et al., 1999; Mistry et al., 2001). Tariquidar has a good oral bioavailability, long duration of action and low potential for toxic side effects, all of which make this a favourable P-gp inhibitor. For example, van Vliet et al. demonstrated that inhibiting P-gp with tariquidar significantly reduced seizure duration, frequency and severity, which improved phenytoin efficacy in a rat model for temporal lobe epilepsy. This suggested that combination of AEDs with a transporter inhibitor may be a promising therapeutic strategy for AED-resistant patients (Van Vliet et al., 2006). The same researchers also found that P-gp over-expression in the temporal hippocampus and parahippocampal cortex of chronic epileptic rats reduced phenytoin levels by about 30% in these brain regions. Treating animals with tariquidar significantly increased phenytoin brain levels in regions with over-expressed P-gp (Van Vliet et al., 2007). Another group found that tariquidar restored the anticonvulsive activity of phenobarbital in drug-resistant rats (Brandt et al., 2006). These animal studies demonstrate that transporter inhibition increases AED blood and brain levels and improves seizure control.

Encouraged by animal studies and case reports that suggested transporter inhibition can be used to overcome AED resistance in epilepsy, clinical trials employing P-gp inhibitors were initiated. Currently, two trials using carvedilol and verapamil to inhibit P-gp in AED refractory patients are ongoing (www.clinicaltrials.gov, #NCT00524134, #NCT01126307). However, while both carvedilol and verapamil are FDA-approved and readily available, neither drug is a highly specific nor potent P-gp inhibitor (Arboix et al., 1997; Takara et al.,

2004). In addition, to effectively inhibit over-expressed P-gp, high inhibitor plasma concentrations will be needed, which carries the risk of drug-drug interactions and toxic side effects (Pennock et al., 1991). In a recent study, add-on treatment with verapamil to improve seizure control in dogs with phenobarbital-resistant epilepsy had to be discontinued due to detrimental effects (Jambroszyk et al., 2011). Thus, since potent and specific inhibitors that can be safely given to patients are currently not available, transporter inhibition does not seem to be a viable treatment option in drug-resistant epilepsy at this point in time.

3.1.2 Modulation of transporter regulation

Targeting signalling pathways that regulate drug efflux transporters is another strategy to overcome transporter-mediated AED resistance. The advantages of this approach are three-fold. First, modulating transporter regulation to increase AED brain delivery may allow fine tuning of the transporter. For example, modulating the molecular switches of a transporter may allow turning it off for a short, controlled period of time to deliver drugs into the brain, after which it can be turned on again. Second, preventing or blocking seizure-induced upregulation of transporters may normalise transporter expression and functional activity, and thus, prevent or block development of transporter-mediated AED resistance. Third, since transporter upregulation in epilepsy has been linked to increased seizure occurrence, prevention of transporter upregulation holds the promise of better seizure control. Thus, mapping the signalling pathways involved in efflux transporter upregulation at the blood-brain barrier in epilepsy can help identify new targets that may potentially be used to overcome transporter-mediated AED resistance and improve seizure treatment.

Several signalling pathways have been identified that regulate P-gp, BCRP, and MRP2 at the blood-brain barrier. For BCRP, the most recent signalling mechanisms include Nrf2, NFKB, COX-2, Pim-1 kinase, and the nuclear receptors CAR and AhR (Kalalinia et al., 2011; Singh et al., 2010; Tan et al., 2010; Wang et al., 2010). Of those, CAR and AhR have been shown to upregulate BCRP at the blood-brain barrier (Tan et al., 2010; Wang et al., 2010), which is the opposite of what one would want to improve AED delivery into the brain. Whether targeting any of the other pathways could be used as a therapeutic strategy in AED-resistant epilepsy is unknown and remains to be determined. MRP2 is also regulated through nuclear receptors (PXR, FXR, CAR; (Bauer et al., 2008; Kast et al., 2002)), but the signalling that upregulates MRP2 in epilepsy is unknown.

Most information on transporter regulation is available for P-gp, where signalling pathways have been shown to be present in various tissues (liver, kidney, intestine; (Ho & Piquette-Miller, 2006; Nawa et al., 2010; Thevenod et al., 2000). They also involve various signalling molecules: inflammatory mediators including TNF- α , ET-1, IL1- β , IL-6, NO; COX-2 (Dixit et al., 2005; Goralski et al., 2003; Nawa et al., 2010; Patel et al., 2002; Poller et al., 2010; Sukhai et al., 2001; Von Wedel-Parlow et al., 2009), nuclear receptors PXR, CAR, AhR, and GR (Bauer et al., 2004; Bauer et al., 2007; Geick et al., 2001; Narang et al., 2008; Wang et al., 2011; Wang et al., 2010), protein kinase C (Bauer et al., 2007; Chambers et al., 1990a; Chambers et al., 1990b; Hartz et al., 2004; Miller et al., 1998; Rigor et al., 2010), and NFKB (Bauer et al., 2007; Bentires-Alj et al., 2003; Kim et al., 2011; Liu et al., 2008; Thevenod et al., 2000; Yu et al., 2008). These pathways have been found in several diseases including Alzheimer's disease, HIV, and diabetes (Hartz et al., 2010; Hayashi et al., 2006; Nawa et al., 2010).

One pathway that involves glutamate signalling through the NMDA receptor (NMDAR) followed by cyclooxygenase -2 (COX-2) and prostaglandin E receptor 1 (EP1) activation seems to be critical for seizure-induced upregulation of P-gp (Figure 3, (Bankstahl et al., 2008; Bauer et al., 2008; Pekcec et al., 2009; Zhu & Liu, 2004)). During seizures, neurons release high amounts of the excitatory neurotransmitter glutamate, which can reach interstitial brain concentrations of 10-100 μ M for a short period of time (Ronne-Engstrom et al., 1992; Ueda & Tsuru, 1995). Zhu and Liu were the first to connect glutamate with P-gp upregulation at the blood-brain barrier. They found that glutamate increased P-gp expression and activity in rat brain microvessel endothelial cells and suggested that activation of the NMDAR plays a critical role in glutamate-mediated P-gp upregulation (Zhu & Liu, 2004). Consistent with this, Bauer et al. demonstrated that exposing isolated rat and mouse brain capillaries to glutamate increased P-gp expression and activity (Bauer et al., 2008). It was shown that glutamate signalling through NMDAR and COX-2 upregulates blood-brain barrier P-gp, and that COX inhibition prevented P-gp upregulation suggesting that AED brain uptake can be enhanced by COX inhibition. Bankstahl et al. confirmed glutamate involvement in seizure-induced P-gp over-expression and that blocking NMDAR prevents P-gp upregulation and neuronal damage *in vivo* (Bankstahl et al., 2008). Another study showed that pre-treatment with celecoxib, a specific COX-2 inhibitor, prevented seizure-induced P-gp upregulation in rat brain capillaries (Zibell et al., 2009), and yet another study demonstrated that pre-treatment with celecoxib for 6 days followed by administration of phenobarbital for 16 days reduced the frequency of spontaneous recurrent seizures and restored the anticonvulsant effect of phenobarbital in AED-resistant epileptic rats (Schlichtiger et al., 2010). van Vliet et al. evaluated the use of the COX-2 inhibitors SC-58236 and NS-398 in rats with recurrent spontaneous seizures. They found that 2-week treatment with these COX-2 inhibitors prevented P-gp upregulation and enhanced phenytoin brain uptake in chronic epileptic rats (Van Vliet et al., 2010). While these studies are promising, COX-2 inhibitors bear the risk of severe cardio- and cerebrovascular side effects (Mukherjee, 2001; Stollberger & Finsterer, 2003). In addition, it has been demonstrated that COX-2 inhibition can lead to increased seizure frequency and mortality in epileptic rats (Holtzman et al., 2010). Thus, although COX-2 inhibition may reduce AED resistance in animal models, it may not be a valid target in the clinic over the long term.




Fig. 3. Glutamate - NMDAR1 - COX-2 - EP1 Signaling Pathway

Another signalling protein involved in glutamate-mediated P-gp upregulation at the blood-brain barrier is the EP1 receptor. EP1 is activated by prostaglandin E2, the main product of COX-2, and was tested as potential target to prevent transporter upregulation in epilepsy. Pekcec et al. found that EP1 is a key signalling protein in the pathway that drives P-gp upregulation during seizures (Pekcec et al., 2009). Studies using the EP1 inhibitors SC-51089 and misoprostol showed that SC-51089 decreased seizure severity in rats when given prior to electrical kindling, but it also prolonged seizure duration at higher doses, whereas misoprostol decreased duration of motor seizure activity (Fischborn et al., 2010).

Together, these studies show that glutamate released during seizures mediates P-gp upregulation through NMDAR, COX-2, and EP1 and that these signalling proteins could potentially be used as therapeutic targets to reduce AED-resistance. Whether this pathway also signals upregulation of other blood-brain barrier proteins is unknown at this time.

3.2 The metabolic blood-brain barrier

Xenobiotic metabolism is a 3-phase process during which low polar molecules (e.g., drugs) are enzymatically converted to polar molecules that are then excreted from the body mostly through bile, faeces, or urine. Most chemicals are pharmacologically or toxicologically inactivated during metabolism, only some are transformed into active metabolites. The liver is recognized as the main site of biotransformation, but extrahepatic tissues such as the kidney, lung, intestine, skin, and brain also contribute to drug metabolism.

The processes involved in the biotransformation of drugs are classified into phase I (functionalisation) and phase II (conjugation) reactions that are followed by phase III excretion of the metabolite (Figure 4). Substrates of phase I enzymes are in general lipophilic and undergo functionalisation reactions such as monooxygenation, dealkylation, reduction, aromatization, or hydrolysis. The modified molecules are substrates for phase II enzymes, which conjugate the functional group with a polar compound, such as an amino acid, sulphate, glutathione, or a sugar (Minn et al., 1991). In the last phase III step, functionalised and conjugated xenobiotics are excreted from cells by efflux transporters.




Fig. 4. Schematic of 3-phase drug metabolism and excretion

Most CNS drugs, including AEDs, have to cross the blood-brain barrier and penetrate into the brain parenchyma to reach their target sites. En passage across the barrier and within the brain, drugs can undergo inactivation and elimination comparable to hepatic drug

metabolism. In the brain, the following phase I enzymes have been identified: monoamine oxidases, CYP P450, NADPH-CYP P450 reductase, and epoxide hydrolases (Chat et al., 1998; Dutheil et al., 2010; Ghersi-Egea et al., 1998; Ghersi-Egea et al., 1988; Ghersi-Egea et al., 1993; Minn et al., 1991; Ravindranath et al., 1990). Phase II enzymes identified in the brain include UDP-glucuronosyltransferase (UGT), phenol sulfotransferase (PST), and GST (Dutheil et al., 2010; Ghersi-Egea et al., 1998; Ghersi-Egea et al., 1988; Ghersi-Egea et al., 1993; Minn et al., 1991). Several phase I and II enzymes have been found in the brain capillary endothelium, where they possibly form a metabolic barrier for drugs en route into the brain (Dutheil et al., 2010; Ghersi-Egea et al., 1998; Ghersi-Egea et al., 1993; Minn et al., 1991; Stamatovic et al., 2008). Several reports on metabolism-coupled efflux transport (phase III) suggest that biotransformation of drugs and efflux of the metabolites are part of barrier function. Together, the rodent and human brain, including brain microvessels forming the blood-brain barrier, express enzymes and transporters that are part of the detoxification pathways that affect metabolism of therapeutic drugs. In addition, AED elimination by coupling of two important biological processes – metabolism and efflux transport - could contribute to AED resistance and intractable epilepsy.

3.2.1 Metabolism of AEDs and the metabolic barrier in epilepsy

Phase I. CYP P450 enzymes are responsible for most phase I metabolic reactions and have the greatest impact on the biotransformation of therapeutic drugs. CYPs form a large and functionally diverse superfamily of enzymes that are found throughout various species ranging from bacteria to humans. In humans, the majority of CYPs are expressed along the inner plasma membranes of mitochondria and the endoplasmic reticulum. Although a distinct group of CYPs (CYP11A1, 11B1, 11B2, 17A1, 21A2) is involved in steroid hormone synthesis in humans (Hrycay & Bandiera, 2009), most CYP enzymes contribute primarily to the elimination of endogenous and exogenous substrates through oxidation to enhance their excretion from the body. By-and-large, CYP-mediated metabolism occurs in the liver and contributes to the “first pass effect” of orally administered drugs. In the liver, several CYPs exist as allelic or genetic variants and such CYP polymorphisms have been shown to influence the plasma concentration of some AEDs. CYPs are also expressed in the kidney and renal excretion is an important elimination route, particularly for most novel AEDs.

With regard to epilepsy it is noteworthy that many AEDs are metabolised by CYPs (**Table 1**). CYP2C9 and CYP2C19 are the two major enzymes involved in AED metabolism including diazepam, phenobarbital, phenytoin, and valproic acid (**Table 1**; (Klotz, 2007)). Several studies demonstrated differences in the biotransformation of these AEDs depending on the underlying CYP genotype. For example: phenytoin metabolism depends on the allelic composition of the gene encoding for CYP2C19 and CYP2C9. Several mutated alleles of these genes are known. Thus, based on genotype, poor phenytoin metabolisers can be distinguished from phenytoin hypermetabolisers and their frequency distributions vary between different ethnic populations (Klotz, 2007).

Regarding CYPs in the brain, *in vitro* and *in vivo* functional expression of CYPs has been detected in various CNS cell types from different species. CYP expression in distinct CNS cell populations is variable but can be as high as in the liver (Bhagwat et al., 2000). Importantly, it has been shown that CYPs are functionally active at the blood-brain barrier (Dutheil et al., 2010).

DRUG	ENZYME/PATHWAY
Carbamazepine	CYP3A4, mEH1 for carbamazepine-10, 11-epoxide
Ethosuximide	CYP3A4?, 10-20% renal
Phenobarbital	CYP2C19, hydroxylation, glucuronidation, 25% renal
Phenytoin	CYP2C9, CYP2C19
Valproate	CYP2C9, glucuronidation, oxidation
Diazepam	CYP2C19, CYP3A4
Felbamate	40-60% renal, hydroxylation, glucuronidation
Gabapentin	Renal
Lamotrigine	Glucuronidation, 8% renal
Levetiracetam	66% renal, hydrolyse
Oxcarbazepine	Reduction to active metabolite that is glucuronidated
Pregabalin	98% renal
Tiagabine	CYP3A4, 25% renal
Topiramate	60-80% renal, oxidation, hydrolysis, glucuronidation
Vigabatrin	60-80% renal
Zonisamide	CYP3A4, N-acetylation, glucuronidation, 30% renal

Table 1. Antiepileptic drugs and their route of biotransformation (modified from Klotz, 2007)

In the human brain, 20 CYP isoforms have been identified so far: CYP1A1, 1A2, 1B1, 2B6, 2C8, 2D6, 2E1, 3A4, 3A5, 8A1, 11A1, 11B1, 11B2, 17A1, 19A1, 21A2, 26A1, 26B1, 27B1, and 46A1 (Dutheil et al., 2010). The exact expression pattern within the CNS depends on the particular CYP and greatly varies between different brain cells. In a recent study, CYP mRNA expression levels were measured in a human brain microvessel cell line and in human microvessels isolated from surgically removed brain tissue from epileptic patients or patients with brain tumours (Dauchy et al., 2008). The authors found mRNA expression of CYP2U1, CYP2S1, CYP2R1, CYP2B6, CYP2E1, CYP1A1, CYP2D6, CYP1B1, CYP2J2, CYP1A2, and CYP2C8. In another study, Ghosh et al. used commercially available human microvascular cerebral endothelial cells and found mRNA expression of CYP1A1, 1B1, 2A6, 2B6, 2C, 2C9, 2E1, 2J2, 3A4, 4A11, 11b, CYP3A5, 4B1, C1, 21A, and 51A1 (Ghosh et al., 2010). The cells that were used for this study originated from surgically resected brain specimens of drug-resistant epileptic patients, brain specimens resected from aneurism domes, commercially available human microvascular cerebral endothelial cells (used as control), and from human umbilical vein endothelial cells (used as control). mRNA expression from 11 of the 16 CYPs was increased in endothelial cells from epileptic tissue compared to microvascular cerebral endothelial cells. Although this comparison may be flawed due to the different nature of these cells, mRNA expression in endothelial cells from drug-resistant epileptic patients was not different compared to brain specimens resected from aneurism domes without seizures (Ghosh et al., 2010). This result argues against a seizure effect on the regulation of blood-brain barrier CYPs. However, it is clear from these findings that more detailed and accurate studies with appropriate controls are needed. Overall, expression profiles, tissue and cellular distribution, and relative expression of CYP enzymes seem to depend on study design and the models used. Therefore, additional research is needed to clarify the importance of individual CYPs at the blood-brain barrier under both physiological and epileptic conditions.

CYP Regulation in the CNS

Carbamazepine induces CYP3A4 protein and mRNA expression in human brain endothelial cells and hepatocytes (Ghosh et al., 2010; Luo et al., 2002). But carbamazepine is metabolized by CYP3A4 (, **Table 1**), and high expression of CYP3A4 protein was found in endothelial cells isolated from surgically resected epileptic brain tissue (Ghosh et al., 2011). Neuronal CYP3A4 expression has also been demonstrated in brain sections by immunostaining from patients with temporal lobe epilepsy, tuberous sclerosis, or cavernous angioma, all of whom had intractable epilepsy. In these samples, CYP3A4 was rarely co-localised with the astrocytic marker GFAP (Ghosh et al., 2011). Carbamazepine given to cells that derived from resected epileptic brain tissue underwent metabolism at an extent similar to what was observed in hepatocytes. Thus, increased CYP3A4 expression and metabolic function could be characteristic for endothelial cells in epilepsy, which could contribute to AED resistance.

As mentioned before, AEDs such as carbamazepine act as strong inducers of hepatic and blood-brain barrier CYP expression, thereby influencing the pharmacokinetics of other drugs. Other AEDs have also been reported to increase CYP expression at the blood-brain barrier and exposure of primary rat brain astrocytic cultures to phenytoin increased Cyp2c29 levels (Volk et al., 1995). Moreover, phenytoin was metabolised by the microsomal fraction of astrocyte cultures and chronic treatment of mice with phenytoin resulted in increased levels of phenytoin metabolites in the brain (Volk et al., 1988). These findings support the idea of dynamic CYP regulation at the blood-brain barrier by AED exposure. In general, regulation of CYPs at the blood-brain barrier could be independent from that in the liver. Support for this comes from studies in alcoholics. Levels of CYP2D6 protein were elevated in the brains of alcoholics compared to non-alcoholics (Dutheil et al., 2010; Miksys & Tyndale, 2004). Particularly high CYP2D6 levels were detected in the putamen, globus pallidus, and substantia nigra, but interestingly, CYP2D6 was not elevated in the liver (Dutheil et al., 2010). Nuclear receptors that act as transcription factors control regulation of CYPs and ABC transporters in the CNS. In the human brain, several nuclear receptors have been detected that could control CYP regulation, including AhR, PXR, FXR, CAR, LXR α , RXR α and β , PPAR- α , - δ , and - γ (Dutheil et al., 2009; Nishimura et al., 2004). For example, Dauchy et al. showed that the AhR agonist TCDD increased mRNA expression of CYP1A1 and CYP1B1 in the human cell line hCMEC/D3 (Dauchy et al., 2008). Thus, it is possible that nuclear receptors could be involved in the regulation of CYPs at the blood-brain barrier in epilepsy (Dauchy et al., 2008; Dauchy et al., 2009; Ghosh et al., 2010). This idea is supported by the fact that metabolites of CYP2J2, which is expressed in brain endothelial cells in epilepsy, activate the nuclear receptors PPAR- α (NR1C1) and PPAR- γ (NR1C3). Future studies are required to address CYP regulation at the blood-brain barrier in health, disease (e.g., epilepsy), and during pharmacotherapy (e.g., AED treatment).

Phase II & III. Metabolism-driven efflux transport, i.e., coupling of phase II and III, has been demonstrated in the liver. Analogous findings from studies at the blood-CSF-barrier show coupling of metabolism and efflux transport also in the CNS. Using cultured rat choroid plexus epithelial cells *in vitro*, Strazielle and Ghersi-Egea demonstrated the presence of a metabolism-driven efflux mechanism for 1-naphthol, a cytotoxic, lipophilic model compound (Strazielle & Ghersi-Egea, 1999). The authors showed that UGT metabolised 1-naphthol *in situ* into a glucurono-conjugate (phase II) that was excreted by an efflux transporter (phase III). In this regard, MRPs have been implicated in cellular export of various glutathione, glucuronide, and sulfate conjugates compounds, and several other

endogenous and xenobiotic compounds (Gerk & Vore, 2002; Jedlitschky et al., 1996; Loe et al., 1996; Oude Elferink & Jansen, 1994). Although Mrp involvement has not directly been shown in Strazielle and Ghersi-Egea's study, Mrp-mediated efflux of the 1-naphthol glucurono-conjugate seems likely as the export was sensitive to the Mrp inhibitor probenecid. Thus, this study demonstrated the biological relevance of metabolism-driven efflux in the brain (Strazielle & Ghersi-Egea, 1999). However, in the human brain, UGT-mediated metabolism of 1-naphthol is less prominent compared to rat brain, and therefore, species differences should be considered (Ghersi-Egea et al., 1993). Activity of another phase II enzyme, GST, seems to be more relevant for human metabolism (Ghersi-Egea et al., 1993). Metabolism-driven transport was shown for GST π and Mrp1 by Leslie et al., who demonstrated plasma membrane co-localisation of Mrp1 and GST π in H69AR cells and found that functional GST π was required for Mrp1-mediated transport (Leslie et al., 2004). mRNA and protein expression of the GST isoform π has been demonstrated in isolated rat and mouse brain capillaries, where GST π is predominantly localized in the cytoplasm and the luminal plasma membrane of brain capillary endothelial cells, and to a large extent, co-localises with Mrp2 in the membrane (Bauer et al., 2008). Consistent with regulation by the nuclear receptor PXR, GST π protein expression increased in membranes from rat brain capillaries exposed to PCN or dexamethasone, and in capillary membranes from rats dosed with PCN. Immunoblotting of the capillary membrane fraction from hPXR transgenic mice dosed with rifampin further showed enhanced GST π expression. GST π and Mrp2 upregulation occurred in parallel, suggesting coordinated regulation of phase-II metabolism and phase-III efflux, i.e. Mrp2-mediated transport (Bauer et al., 2008). While these studies provide first insight into the regulation of both GST π and Mrp2 in brain capillaries, direct proof of metabolism-coupled efflux transport of chemicals at the blood-brain barrier remains to be shown. Thus, metabolism-coupled excretion of CNS drugs, such as AEDs, by efflux transporters seems likely, but requires further studies. Such studies would have to take into consideration the specific conditions at the human blood-brain barrier. For example, human cerebral microvessels show absence of glucuronidation, low NADPH CYP reductase activity, high GST activity, and pronounced epoxide hydrolase activity (Ghersi-Egea et al., 1993). Understanding metabolising enzymes, specifically at the human blood-brain barrier with respect to their physiological function, regulation in health and disease, and interplay with efflux transporters will allow assessing their impact on drug delivery to the brain, particularly in epilepsy.

3.3 Blood-brain barrier leakage in epilepsy

Seizures are accompanied by impaired blood-brain barrier integrity. This has been observed before, during and after seizures in both experimentally induced seizures in animals as well as in epileptic patients (Cornford & Oldendorf, 1986; Horowitz et al., 1992; Mihaly & Bozoky, 1984; Nitsch & Klatzo, 1983; Padou et al., 1995). As a consequence, impaired blood-brain barrier integrity causes transient barrier leakage, which allows entry of blood borne molecules into the brain (Ndode-Ekane et al., 2010; Seiffert et al., 2004; Sokrab et al., 1989; Van Vliet et al., 2007). It has been shown that seizure duration correlates with reduced barrier function (Cornford & Oldendorf, 1986), and it has been demonstrated that increased blood-brain barrier permeability in epilepsy is limited to anatomically specific brain regions (Bradbury, 1979; Cornford et al., 1998; Nitsch & Klatzo, 1983; Oztas & Sandalci, 1984). Interestingly, brain regions with increased barrier permeability are often anatomically

congruent with the brain regions that are implicated in the development and propagation of seizures. Consistent with this observation, extravasation of blood components into the brain correlates with increased excitability, occurrence of seizures, and epilepsy progression (Friedman et al., 2009; Marchi et al., 2007; Ndode-Ekane et al., 2010; Oby & Janigro, 2006; Seiffert et al., 2004; Tomkins et al., 2008; Van Vliet et al., 2007).

Cause of Blood-Brain Barrier Leakage by Seizures. Studies conducted over the last 3 decades indicate that possibly 3 mechanisms could be involved in causing blood-brain barrier leakage in epilepsy: blood pressure, pinocytosis, and seizure-induced inflammation.

Blood Pressure

The first studies conducted in the 1970s showed that arterial blood pressure is involved in seizure-associated blood-brain barrier leakage (Nitsch & Klatzo, 1983). Several studies unequivocally demonstrated that hypertension has detrimental effects on blood-brain barrier integrity and contributes to barrier leakage (Cornford & Oldendorf, 1986; Lee & Olszewski, 1961; Petito et al., 1977; Westergaard, 1980). Johansson summarized three factors responsible for increased blood-brain barrier permeability: (1) maximal arterial blood pressure, (2) duration of maximal arterial blood pressure, and (3) total increase in blood pressure (Johansson, 1981). The detailed mechanism through which increased blood pressure contributes to barrier leakage is unclear, but a working hypothesis postulates the following (Petito et al., 1977): Neuronal hyperactivity (seizures) leads to increased metabolism, and to an increased nutrient and oxygen demand in the involved brain regions. In turn, cerebral blood flow rises and large cerebral arteries dilate, which leads to increased blood pressure in brain capillaries, small arteries and veins (Ndode-Ekane et al., 2010), and triggers barrier leakage. Consistent with this, extravasation of blood albumin into the brain was found specifically in regions with more EEG spiking activity in humans (Cornford et al., 1998). However, the duration of increased blood pressure is critical and determines the severity of barrier leakage. Thus, more severe seizures that are followed by prolonged blood pressure elevations result in a higher increase in barrier permeability (Oztas & Kaya, 1991; Oztas & Sandalci, 1984). This is also supported by studies where both increased arterial blood pressure and subsequently induced barrier leakage were prevented by cervical cordotomy (Schaefer et al., 1975; Westergaard et al., 1978).

Pinocytosis

It was hypothesized that pinocytosis is involved in transport across the capillary endothelium, thus, affecting barrier permeability (Palade, 1961). The pinocytosis rate at the blood-brain barrier is low, which contributes to a tight barrier endothelium. However, Petito et al. observed that seizure-induced blood-brain barrier leakage correlates with increased micropinocytosis (Petito et al., 1977). In an elegant study using intravenous HRP injections in adult male rats with seizures, the authors made two important findings: (1) Brain capillary vesicles from animals that suffered seizures did contain HRP compared to vesicles from control animals that did not contain HRP; (2) the number of HRP-containing vesicles was higher directly after seizures (within 30 sec of last seizure (Petito et al., 1977)). From these observations the authors concluded that an increased micropinocytosis rate during and shortly after seizures increases blood-brain barrier permeability and counteracts barrier function. Nitsch and Hubauer confirmed these studies and showed in kainic acid-injected rats that blood-brain barrier opening was due to increased transendothelial pinocytosis, while tight junctions stayed intact (Nitsch & Hubauer, 1986).

Seizure-induced Inflammation

Another factor causing barrier leakage in epilepsy is seizure-induced inflammation that could be enhanced by extravasation of blood-borne components into the brain. It has been shown that blood-brain barrier permeability is increased by inflammatory mediators, including histamine, substance P, endothelin-1, bradykinin, VEGF, TGF β , IL1 β , TNF α , INF γ , PGE2, PGF2a, chemokines, free radicals, and other factors such as metalloproteinases, thrombin, amyloid- β , intracellular calcium, and leukocytes that directly interact with endothelial cells (Stamatovic et al., 2008). Only limited information is available on how these factors alter the blood-brain barrier but some, e.g., IL1 β and chemokines, seem to exclusively affect paracellular permeability (Stamatovic et al., 2008). It is currently unknown if secretion of these factors is a direct consequence of epileptic seizures. In addition, depending on epilepsy aetiopathology, the composition of the inflammatory "cocktail" and the contribution of individual inflammatory mediators to blood-brain barrier damage could vary significantly. The effect of inflammation on barrier permeability is context-dependent, complex and not well understood. It likely depends on the model, dose, time and location of the inflammatory mediators involved.

One hypothesis that could explain some of the phenomena observed at the blood-brain barrier in epilepsy is that seizure-released glutamate activates signalling reducing barrier integrity and increasing permeability. Glutamate release occurs during seizures at sites in the brain with excessive neuronal activity. On the one hand, high glutamate levels are cytotoxic, which contributes to brain damage. On the other hand, subtoxic glutamate levels trigger molecular processes such as local release and activation of matrix-degrading enzymes that breach integrity (Michaluk & Kaczmarek, 2007; Nishijima et al., 2010). It is possible that glutamate-initiated signalling and inflammatory mediators cause barrier leakage and breakdown in epilepsy. Such events would allow extravasation of blood-borne compounds. Whether this scenario is part of seizures remains to be shown.

Consequences of Blood-Brain Barrier Leakage in Epilepsy. Epilepsy is often a consequence of a prior brain insult (e.g., traumatic brain injury, stroke) and seizures are a symptom of an underlying brain disorder (e.g., brain tumour, Alzheimer's disease, brain inflammation; (Marchi et al., 2006; Salazar et al., 1985; Tomkins et al., 2011). Although the factors that are involved in the development of epilepsy remain unclear, impaired barrier function is common after an initial brain insult and likely contributes to epilepsy pathology. This particular topic has recently attracted major interest in the epileptology field.

It has been shown in patients that brain injury, post-ischemic or vascular inflammation often cause seizures and barrier leakage (Stamatovic et al., 2008; Tomkins et al., 2011; Tomkins et al., 2008). The blood-brain barrier is also impaired in epileptic patients and in seizure animal models, and consequently, it has been postulated that barrier leakage is involved in epilepsy aetiology (Friedman et al., 2009; Marchi et al., 2007; Ndode-Ekane et al., 2010; Oby & Janigro, 2006; Seiffert et al., 2004; Tomkins et al., 2011; Tomkins et al., 2008; Van Vliet et al., 2007). In addition, it has been shown that osmotic barrier opening causes seizures (Oby & Janigro, 2006). However, not all implications of barrier opening have been studied. It is known that intra-arterial injection of hyperosmotic mannitol in patients and rodents results in EEG changes and induces seizures (Fieschi et al., 1980). In a recent study, Marchi et al (2007) observed seizures in patients undergoing osmotic barrier opening for delivering chemotherapeutics to treat brain lymphomas. In 25% of patients, seizure onset occurred

immediately after barrier opening. Using a pig model, the authors demonstrated that seizure occurrence correlated with barrier opening and was neither attributed to the existing brain lymphoma nor to chemotherapy (Marchi et al., 2007).

The molecular and cellular events that are triggered by barrier opening and that result in seizures and neuronal hyperactivity are a matter of research. Rigau et al. (2007) demonstrated loss of functional tight junctions and immunoglobulin leakage into the brain in surgically resected hippocampal tissue from AED-resistant epilepsy patients (Rigau et al., 2007). Additional evidence from rodents and resected epileptogenic human brain tissue shows that extravasation of albumin into the brain triggers epileptogenesis (Friedman et al., 2009; Ivens et al., 2010). It was shown that astrocytes incorporated extravasated albumin, which induced proepileptogenic transformations, including reduced expression of potassium and aquaporin channels and gap junction proteins, impairment of astrocytic glutamate metabolism, and increased release of pro-inflammatory mediators (Friedman et al., 2009). All these changes had detrimental effects on seizure threshold and susceptibility (Friedman et al., 2009). One could postulate that seizures or other factors that induce barrier leakage trigger albumin extravasation with subsequent astrocytic transformation eventually causing seizures. Such a scenario implies a pernicious feedback loop where seizures drive barrier leakage leading to more seizures. Although this hypothesis is a matter of discussion, many epileptologists are convinced that 'seizures beget seizures' and that epilepsy has a progressive nature (Hauser & Lee, 2002). In this regard, alterations of the blood-brain barrier and extravasation of blood-borne compounds could be a critical part of epilepsy pathology that could potentially be a target for new therapies.

4. Conclusions

Research over the last century demonstrated a key role of the blood-brain barrier in the development of epilepsy and AED resistance. Despite the advances that have been made, what we currently know about AED resistance is mostly limited to descriptive observations rather than understanding of the mechanisms underlying the disease. We know that the blood-brain barrier is altered in epilepsy including changes in transporters, metabolic enzymes, and tight junctions. We also know that transporters, enzymes and tight junctions are affected by and/or contribute to epilepsy pathology. Yet, whether each of these molecular players is part of a cause-effect jigsaw puzzle and how each of the pieces fit together is unclear. Thus, AED resistance in epilepsy remains an unsolved clinical problem. To solve this problem future studies will have to address the mechanism of AED resistance at the molecular level taking all aspects into account in a "big picture approach" rather than focusing on one single piece of the puzzle. The stimuli of blood-brain barrier transporter, enzyme and tight junction regulation in epilepsy will have to be identified and the detailed chain of signalling events will have to be unravelled. Such information will provide novel targets and therapeutic strategies that hold the promise to advance this research field and eventually improve treatment of patients with AED-resistant epilepsy.

5. Acknowledgments

We thank Britt Johnson for editorial assistance. This work was supported by UMN startup funds for A.M.S.H. and B.B.

6. References

Aird, R.B. (1939). Mode of action of brilliant vital red in epilepsy. *Archives of Neurology and Psychiatry* Vol.42, pp.700-723

Al-Anizy, M. et al. (2006). Cytochrome P450 Cyp4x1 is a major P450 protein in mouse brain. *FEBS J*, Vol.273, No.5, (Mar), pp.936-947, ISSN 1742-464X

Arboix, M. et al. (1997). Multidrug resistance-reversing agents increase vinblastine distribution in normal tissues expressing the P-glycoprotein but do not enhance drug penetration in brain and testis. *Journal of Pharmacology and Experimental Therapeutics*, Vol.281, No.3, (Jun), pp.1226-1230, ISSN 0022-3565

Aronica, E. et al. (2004). Expression and cellular distribution of multidrug resistance-related proteins in the hippocampus of patients with mesial temporal lobe epilepsy. *Epilepsia*, Vol.45, No.5, (May), pp.441-451, ISSN 0013-9580

Aronica, E. et al. (2005). Localization of breast cancer resistance protein (BCRP) in microvessel endothelium of human control and epileptic brain. *Epilepsia*, Vol.46, No.6, (Jun), pp.849-857, ISSN 0013-9580

Awasthi, S. et al. (2005). RLIP76, a non-ABC transporter, and drug resistance in epilepsy. *BMC Neurosci*, Vol.6, pp.61, ISSN 1471-2202

Bankstahl, J.P. et al. (2008). Glutamate is critically involved in seizure-induced overexpression of P-glycoprotein in the brain. *Neuropharmacology*, Vol.54, No.6, (May), pp.1006-1016, ISSN 0028-3908

Bauer, B. et al. (2004). Pregnane X receptor up-regulation of P-glycoprotein expression and transport function at the blood-brain barrier. *Molecular Pharmacology*, Vol.66, No.3, (Sep), pp.413-419, ISSN 0026-895X

Bauer, B. et al. (2007). Tumor necrosis factor alpha and endothelin-1 increase P-glycoprotein expression and transport activity at the blood-brain barrier. *Molecular Pharmacology*, Vol.71, No.3, (Mar), pp.667-675, ISSN 0026-895X

Bauer, B. et al. (2008). Seizure-induced up-regulation of P-glycoprotein at the blood-brain barrier through glutamate and cyclooxygenase-2 signaling. *Molecular Pharmacology*, Vol.73, No.5, (May), pp.1444-1453, ISSN 1521-0111

Begley, D.J. (2004). Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. *Pharmacology and Therapeutics*, Vol.104, No.1, (Oct), pp.29-45, ISSN 0163-7258

Bentires-Alj, M. et al. (2003). NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells. *Oncogene*, Vol.22, No.1, (Jan 9), pp.90-97, ISSN 0950-9232

Bercel, N.A. (1955). Diuretics in therapy of epilepsy; their use for the potentiation of anticonvulsant drugs. *California Medicine*, Vol.82, No.2, (Feb), pp.107-110, ISSN 0008-1264

Betz, A.L. et al. (1980). Polarity of the blood-brain barrier: distribution of enzymes between the luminal and antiluminal membranes of brain capillary endothelial cells. *Brain Research*, Vol.192, No.1, (Jun 16), pp.17-28

Beuckmann, C. et al. (1995). Induction of the blood/brain-barrier-associated enzyme alkaline phosphatase in endothelial cells from cerebral capillaries is mediated via cAMP. *European Journal of Biochemistry*, Vol.229, No.3, (May 1), pp.641-644, ISSN 0014-2956

Bhagwat, S.V. et al. (2000). Multiple forms of cytochrome P450 and associated monooxygenase activities in human brain mitochondria. *Biochemical Pharmacology*, Vol.59, No.5, (Mar 1), pp.573-582, ISSN 0006-2952

Boado, R.J. et al. (2004). Developmental regulation of the rabbit blood-brain barrier LAT1 large neutral amino acid transporter mRNA and protein. *Pediatric Research*, Vol.55, No.4, (Apr), pp.557-560, ISSN 0031-3998

Bolwig, T.G. et al. (1977). Acute hypertension causing blood-brain barrier breakdown during epileptic seizures. *Acta Neurologica Scandinavica*, Vol.56, No.4, (Oct), pp.335-342, ISSN 0001-6314

Bradbury, M.W.B. (1979) *The Concept of a Blood-Brain Barrier*. John Wiley, Chichester.

Brandt, C. et al. (2006). The multidrug transporter hypothesis of drug resistance in epilepsy: Proof-of-principle in a rat model of temporal lobe epilepsy. *Neurobiology of Disease*, Vol.24, No.1, (Oct), pp.202-211, ISSN 0969-9961

Braun, D. et al. (2011). Developmental and cell type-specific expression of thyroid hormone transporters in the mouse brain and in primary brain cells. *Glia*, Vol.59, No.3, (Mar), pp.463-471, ISSN 1098-1136

Brightman, M.W. & Reese, T.S. (1969). Junctions between intimately apposed cell membranes in the vertebrate brain. *Journal of Cell Biology*, Vol.40, No.3, (Mar), pp.648-677

Cervey, L. et al. (2006). Lack of interactions between breast cancer resistance protein (bcrp/abcg2) and selected antiepileptic agents. *Epilepsia*, Vol.47, No.3, (Mar), pp.461-468, ISSN 0013-9580

Chambers, T.C. et al. (1990a). Correlation of protein kinase C translocation, P-glycoprotein phosphorylation and reduced drug accumulation in multidrug resistant human KB cells. *Biochemical and Biophysical Research Communications*, Vol.169, No.1, (May 31), pp.253-259, ISSN 0006-291X

Chambers, T.C. et al. (1990b). Protein kinase C phosphorylates P-glycoprotein in multidrug resistant human KB carcinoma cells. *Journal of Biological Chemistry*, Vol.265, No.13, (May 5), pp.7679-7686, ISSN 0021-9258

Chat, M. et al. (1998). Drug metabolizing enzyme activities and superoxide formation in primary and immortalized rat brain endothelial cells. *Life Sciences*, Vol.62, No.2, pp.151-163, ISSN 0024-3205

Chen, Y. et al. (2009). P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib. *Journal of Pharmacology and Experimental Therapeutics*, Vol.330, No.3, (Sep), pp.956-963, ISSN 1521-0103

Clarke, H.B. & Gabrielsen, T.O. (1989). Seizure induced disruption of blood-brain barrier demonstrated by CT. *Journal of Computer Assisted Tomography*, Vol.13, No.5, (Sep-Oct), pp.889-892, ISSN 0363-8715

Cobb, S. et al. (1938). Anticonvulsive action of vital dyes. *Archives of Neurology and Psychiatry*, Vol.40, pp.1156-1177

Cornford, E.M. et al. (1998). Interictal seizure resections show two configurations of endothelial Glut1 glucose transporter in the human blood-brain barrier. *Journal of Cerebral Blood Flow and Metabolism*, Vol.18, No.1, (Jan), pp.26-42, ISSN 0271-678X

Cornford, E.M. & Oldendorf, W.H. (1986). Epilepsy and the blood-brain barrier. *Advances in Neurology*, Vol.44, pp.787-812, ISSN 0091-3952

Crowe, A. & Teoh, Y.K. (2006). Limited P-glycoprotein mediated efflux for anti-epileptic drugs. *Journal of Drug Targeting*, Vol.14, No.5, (Jun), pp.291-300, ISSN 1061-186X

Cucullo, L. et al. (2007). Development of a humanized in vitro blood-brain barrier model to screen for brain penetration of antiepileptic drugs. *Epilepsia*, Vol.48, No.3, (Mar), pp.505-516, ISSN 0013-9580

Dauchy, S. et al. (2008). ABC transporters, cytochromes P450 and their main transcription factors: expression at the human blood-brain barrier. *Journal of Neurochemistry*, Vol.107, No.6, (Dec), pp.1518-1528, ISSN 1471-4159

Dauchy, S. et al. (2009). Expression and transcriptional regulation of ABC transporters and cytochromes P450 in hCMEC/D3 human cerebral microvascular endothelial cells. *Biochemical Pharmacology*, Vol.77, No.5, (Mar 1), pp.897-909, ISSN 1873-2968

De Vries, N.A. et al. (2007). P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan. *Clinical Cancer Research*, Vol.13, No.21, (Nov 1), pp.6440-6449, ISSN 1078-0432

Del Amo, E.M. et al. (2008). Pharmacokinetic role of L-type amino acid transporters LAT1 and LAT2. *European Journal of Pharmaceutical Sciences*, Vol.35, No.3, (Oct 2), pp.161-174, ISSN 0928-0987

Devinsky, O. (1999). Patients with refractory seizures. *New England Journal of Medicine*, Vol.340, No.20, (May 20), pp.1565-1570, ISSN 0028-4793

Dixit, S.G. et al. (2005). Nitric oxide mediates increased P-glycoprotein activity in interferon- $\{\gamma\}$ -stimulated human intestinal cells. *Am J Physiol Gastrointest Liver Physiol*, Vol.288, No.3, (Mar), pp.G533-540, ISSN 0193-1857

Dombrowski, S.M. et al. (2001). Overexpression of multiple drug resistance genes in endothelial cells from patients with refractory epilepsy. *Epilepsia*, Vol.42, No.12, (Dec), pp.1501-1506, ISSN 0013-9580

Dutheil, F. et al. (2009). Xenobiotic-metabolizing enzymes and transporters in the normal human brain: regional and cellular mapping as a basis for putative roles in cerebral function. *Drug Metabolism and Disposition: The Biological Fate of Chemicals*, Vol.37, No.7, (Jul), pp.1528-1538, ISSN 1521-009X

Dutheil, F. et al. (2010). ABC transporters and cytochromes P450 in the human central nervous system: influence on brain pharmacokinetics and contribution to neurodegenerative disorders. *Expert Opin Drug Metab Toxicol*, Vol.6, No.10, (Oct), pp.1161-1174, ISSN 1744-7607

Ehrlich, P. (1885). Das Sauerstoff-Bedürfniss des Organismus. Eine farbenanalytische Studie. *Verlag von August Hischwald*, pp.1-167

Fieschi, C. et al. (1980). Effects on EEG of the osmotic opening of the blood-brain barrier in rats. *Life Sciences*, Vol.27, No.3, (Jul 21), pp.239-243, ISSN 0024-3205

Filbrandt, C.R. et al. (2004). Presence and functional activity of the aryl hydrocarbon receptor in isolated murine cerebral vascular endothelial cells and astrocytes. *Neurotoxicology*, Vol.25, No.4, (Jun), pp.605-616, ISSN 0161-813X

Fischborn, S.V. et al. (2010). Targeting the prostaglandin E2 EP1 receptor and cyclooxygenase-2 in the amygdala kindling model in mice. *Epilepsy Research*, Vol.91, No.1, (Sep), pp.57-65, ISSN 1872-6844

Friedman, A. et al. (2009). Blood-brain barrier breakdown-inducing astrocytic transformation: novel targets for the prevention of epilepsy. *Epilepsy Research*, Vol.85, No.2-3, (Aug), pp.142-149, ISSN 1872-6844

Geick, A. et al. (2001). Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. *Journal of Biological Chemistry*, Vol.276, No.18, (May 4), pp.14581-14587, ISSN 0021-9298

Gerk, P.M. & Vore, M. (2002). Regulation of expression of the multidrug resistance-associated protein 2 (MRP2) and its role in drug disposition. *Journal of Pharmacology and Experimental Therapeutics*, Vol.302, No.2, (Aug), pp.407-415, ISSN 0022-3565

Ghersi-Egea, J.F. et al. (1994). Localization of drug-metabolizing enzyme activities to blood-brain interfaces and circumventricular organs. *Journal of Neurochemistry*, Vol.62, No.3, (Mar), pp.1089-1096, ISSN 0022-3042

Ghersi-Egea, J.F. et al. (1998). Electronic spin resonance detection of superoxide and hydroxyl radicals during the reductive metabolism of drugs by rat brain preparations and isolated cerebral microvessels. *Free Radical Biology and Medicine*, Vol.24, No.7-8, (May), pp.1074-1081, ISSN 0891-5849

Ghersi-Egea, J.F. et al. (1988). A new aspect of the protective functions of the blood-brain barrier: activities of four drug-metabolizing enzymes in isolated rat brain microvessels. *Life Sciences*, Vol.42, No.24, pp.2515-2523, ISSN 0024-3205

Ghersi-Egea, J.F. et al. (1993). Subcellular localization of cytochrome P450, and activities of several enzymes responsible for drug metabolism in the human brain. *Biochemical Pharmacology*, Vol.45, No.3, (Feb 9), pp.647-658, ISSN 0006-2952

Ghersi-Egea, J.F. et al. (1987). Quantitative measurement of cerebral cytochrome P-450 by second derivative spectrophotometry. *Journal of Neuroscience Methods*, Vol.20, No.3, (Jul), pp.261-269, ISSN 0165-0270

Ghosh, C. et al. (2010). Pattern of P450 expression at the human blood-brain barrier: roles of epileptic condition and laminar flow. *Epilepsia*, Vol.51, No.8, (Aug), pp.1408-1417, ISSN 1528-1167

Ghosh, C. et al. (2011). Cellular localization and functional significance of CYP3A4 in the human epileptic brain. *Epilepsia*, Vol.52, No.3, (Mar), pp.562-571, ISSN 1528-1167

Goldmann, E.E. (1909). Die äussere und innere Sekretion des gesunden und kranken Organismus im Lichte der "vitalen Färbung". *Beiträge zur klinischen Chirurgie*, Vol.64, pp.192-265

Goldmann, E.E. (1913) *Vitalfärbung am Zentralnervensystem. Beitrag zur Physio-Pathologie des Plexus Chorioideus und der Hirnhäute*. Verlag der königlichen Akademie der Wissenschaften, Berlin.

Goldstein, G.W. & Betz, A.L. (1983). Recent advances in understanding brain capillary function. *Annals of Neurology*, Vol.14, No.4, (Oct), pp.389-395

Goralski, K.B. et al. (2003). Downregulation of mdr1a expression in the brain and liver during CNS inflammation alters the in vivo disposition of digoxin. *British Journal of Pharmacology*, Vol.139, No.1, (May), pp.35-48, ISSN 0007-1188

Hartz, A.M. et al. (2004). Rapid regulation of P-glycoprotein at the blood-brain barrier by endothelin-1. *Molecular Pharmacology*, Vol.66, No.3, (Sep), pp.387-394, ISSN 0026-895X

Hartz, A.M. et al. (2010). Restoring blood-brain barrier P-glycoprotein reduces brain amyloid-beta in a mouse model of Alzheimer's disease. *Molecular Pharmacology*, Vol.77, No.5, (May), pp.715-723, ISSN 1521-0111

Hauser, W.A. & Lee, J.R. (2002). Do seizures beget seizures? *Progress in Brain Research*, Vol.135, pp.215-219, ISSN 0079-6123

Hayashi, K. et al. (2006). HIV-TAT protein upregulates expression of multidrug resistance protein 1 in the blood-brain barrier. *Journal of Cerebral Blood Flow and Metabolism*, Vol.26, No.8, (Aug), pp.1052-1065, ISSN 0271-678X

Ho, E.A. & Piquette-Miller, M. (2006). Regulation of multidrug resistance by pro-inflammatory cytokines. *Curr Cancer Drug Targets*, Vol.6, No.4, (Jun), pp.295-311, ISSN 1568-0096

Hoffmann, K. et al. (2006). Expression of the multidrug transporter MRP2 in the blood-brain barrier after pilocarpine-induced seizures in rats. *Epilepsy Research*, Vol.69, No.1, (Apr), pp.1-14, ISSN 0920-1211

Holtzman, L. et al. (2010). Cox-2 inhibition can lead to adverse effects in a rat model for temporal lobe epilepsy. *Epilepsy Research*, Vol.91, No.1, (Sep), pp.49-56, ISSN 1872-6844

Horowitz, S.W. et al. (1992). Complex partial seizure-induced transient MR enhancement. *Journal of Computer Assisted Tomography*, Vol.16, No.5, (Sep-Oct), pp.814-816, ISSN 0363-8715

Hrycay, E.G. & Bandiera, S.M. (2009). Expression, function and regulation of mouse cytochrome P450 enzymes: comparison with human P450 enzymes. *Curr Drug Metab*, Vol.10, No.10, (Dec), pp.1151-1183, ISSN 1875-5453

Huber, J.D. et al. (2001). Molecular physiology and pathophysiology of tight junctions in the blood-brain barrier. *Trends in Neurosciences*, Vol.24, No.12, (Dec), pp.719-725, ISSN

Iannetti, P. et al. (2005). Calcium-channel blocker verapamil administration in prolonged and refractory status epilepticus. *Epilepsia*, Vol.46, No.6, (Jun), pp.967-969, ISSN 0013-9580

Ito, K. et al. (2011). Quantitative membrane protein expression at the blood-brain barrier of adult and younger cynomolgus monkeys. *Journal of Pharmaceutical Sciences*, (Jan 19), pp., ISSN 1520-6017

Ivens, S. et al. (2010). Blood-brain barrier breakdown as a novel mechanism underlying cerebral hyperperfusion syndrome. *Journal of Neurology*, Vol.257, No.4, (Apr), pp.615-620, ISSN 1432-1459

Jambroszyk, M. et al. (2011). Add-on treatment with verapamil in pharmacoresistant canine epilepsy. *Epilepsia*, Vol.52, No.2, (Feb), pp.284-291, ISSN 1528-1167

Jedlitschky, G. et al. (1996). Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump. *Cancer Research*, Vol.56, No.5, (Mar 1), pp.988-994, ISSN 0008-5472

Johansson, B.B. (1981). Indomethacin and cerebrovascular permeability to albumin in acute hypertension and cerebral embolism in the rat. *Experimental Brain Research*, Vol.42, No.3-4, pp.331-336, ISSN 0014-4819

Kalalinia, F. et al. (2011). Potential role of cyclooxygenase-2 on the regulation of the drug efflux transporter ABCG2 in breast cancer cell lines. *Journal of Cancer Research and Clinical Oncology*, Vol.137, No.2, (Feb), pp.321-330, ISSN 1432-1335

Kamiie, J. et al. (2008). Quantitative atlas of membrane transporter proteins: development and application of a highly sensitive simultaneous LC/MS/MS method combined with novel in-silico peptide selection criteria. *Pharmaceutical Research*, Vol.25, No.6, (Jun), pp.1469-1483, ISSN 0724-8741

Kast, H.R. et al. (2002). Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. *Journal of Biological Chemistry*, Vol.277, No.4, (Jan 25), pp.2908-2915, ISSN 0021-9258

Kim, H.G. et al. (2011). Metformin inhibits P-glycoprotein expression via the NF- κ B pathway and CRE transcriptional activity through AMPK activation. *British Journal of Pharmacology*, Vol.162, No.5, (Mar), pp.1096-1108, ISSN 1476-5381

Kitano, T. et al. (2002). Polarized glucose transporters and mRNA expression properties in newly developed rat syncytiotrophoblast cell lines, TR-TBTs. *Journal of Cellular Physiology*, Vol.193, No.2, (Nov), pp.208-218, ISSN 0021-9541

Klotz, U. (2007). The role of pharmacogenetics in the metabolism of antiepileptic drugs: pharmacokinetic and therapeutic implications. *Clinical Pharmacokinetics*, Vol.46, No.4, pp.271-279, ISSN 0312-5963

Kniesel, U. & Wolburg, H. (2000). Tight junctions of the blood-brain barrier. *Cellular and Molecular Neurobiology*, Vol.20, No.1, (Feb), pp.57-76

Kubota, H. et al. (2006). Distribution and functional activity of P-glycoprotein and multidrug resistance-associated proteins in human brain microvascular endothelial cells in hippocampal sclerosis. *Epilepsy Research*, Vol.68, No.3, (Mar), pp.213-228, ISSN 0920-1211

Kuteykin-Teplyakov, K. et al. (2009). Complex time-dependent alterations in the brain expression of different drug efflux transporter genes after status epilepticus. *Epilepsia*, Vol.50, No.4, (Apr), pp.887-897, ISSN 1528-1167

Kwan, P. & Brodie, M.J. (2003). Clinical trials of antiepileptic medications in newly diagnosed patients with epilepsy. *Neurology*, Vol.60, No.11 Suppl 4, (Jun 10), pp.S2-12, ISSN 1526-632X

Lazarowski, A. et al. (2007). ABC transporters during epilepsy and mechanisms underlying multidrug resistance in refractory epilepsy. *Epilepsia*, Vol.48 Suppl 5, pp.140-149, ISSN 0013-9580

Lazarowski, A. et al. (1999). Tuberous sclerosis associated with MDR1 gene expression and drug-resistant epilepsy. *Pediatric Neurology*, Vol.21, No.4, (Oct), pp.731-734, ISSN 0887-8994 (Print)

Lee, J.C. & Olszewski, J. (1961). Increased cerebrovascular permeability after repeated electroshocks. *Neurology*, Vol.11, (Jun), pp.515-519, ISSN 0028-3878

Leslie, E.M. et al. (2004). Arsenic transport by the human multidrug resistance protein 1 (MRP1/ABCC1). Evidence that a tri-glutathione conjugate is required. *Journal of Biological Chemistry*, Vol.279, No.31, (Jul 30), pp.32700-32708, ISSN 0021-9258

Lewandowsky, M. (1900). Zur Lehre von der Cerebrospinalflüssigkeit. *Zeitschrift für Klinische Medizin*, Vol.40, pp.480-494

Lin, C.J. et al. (2010). Cellular localization of the organic cation transporters, OCT1 and OCT2, in brain microvessel endothelial cells and its implication for MPTP transport

across the blood-brain barrier and MPTP-induced dopaminergic toxicity in rodents. *Journal of Neurochemistry*, Vol.114, No.3, (Aug), pp.717-727, ISSN 1471-4159

Liu, X. et al. (2008). Progress in brain penetration evaluation in drug discovery and development. *Journal of Pharmacology and Experimental Therapeutics*, Vol.325, No.2, (May), pp.349-356, ISSN 1521-0103

Liu, X. et al. (2007). Increased P-glycoprotein expression and decreased phenobarbital distribution in the brain of pentylenetetrazole-kindled rats. *Neuropharmacology*, Vol.53, No.5, (Oct), pp.657-663, ISSN 0028-3908

Loe, D.W. et al. (1996). Multidrug resistance protein (MRP)-mediated transport of leukotriene C4 and chemotherapeutic agents in membrane vesicles. Demonstration of glutathione-dependent vincristine transport. *Journal of Biological Chemistry*, Vol.271, No.16, (Apr 19), pp.9675-9682, ISSN 0021-9258

Loscher, W. & Potschka, H. (2005). Drug resistance in brain diseases and the role of drug efflux transporters. *Nat Rev Neurosci*, Vol.6, No.8, (Aug), pp.591-602, ISSN 1471-003X

Luo, G. et al. (2002). CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. *Drug Metabolism and Disposition: The Biological Fate of Chemicals*, Vol.30, No.7, (Jul), pp.795-804, ISSN 0090-9556

Maines, L.W. et al. (2005). Evaluation of the role of P-glycoprotein in the uptake of paroxetine, clozapine, phenytoin and carbamazepine by bovine retinal endothelial cells. *Neuropharmacology*, Vol.49, No.5, (Oct), pp.610-617, ISSN 0028-3908

Marchi, N. et al. (2007). Seizure-promoting effect of blood-brain barrier disruption. *Epilepsia*, Vol.48, No.4, (Apr), pp.732-742, ISSN 0013-9580

Marchi, N. et al. (2006). Determinants of drug brain uptake in a rat model of seizure-associated malformations of cortical development. *Neurobiology of Disease*, Vol.24, No.3, (Dec), pp.429-442, ISSN 0969-9961

Marchi, N. et al. (2005). A pilot study on brain-to-plasma partition of 10,11-dihydro-10-hydroxy-5H-dibenzo(b,f)azepine-5-carboxamide and MDR1 brain expression in epilepsy patients not responding to oxcarbazepine. *Epilepsia*, Vol.46, No.10, (Oct), pp.1613-1619, ISSN 0013-9580

Marchi, N. et al. (2004). Significance of MDR1 and multiple drug resistance in refractory human epileptic brain. *BMC Med*, Vol.2, (Oct 9), pp.37, ISSN 1741-7015

Martin, C. et al. (1999). The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein. *British Journal of Pharmacology*, Vol.128, No.2, (Sep), pp.403-411, ISSN 0007-1188

Matter, K. & Balda, M.S. (2003a). Holey barrier: claudins and the regulation of brain endothelial permeability. *Journal of Cell Biology*, Vol.161, No.3, (May 12), pp.459-460, ISSN 0021-9525

Matter, K. & Balda, M.S. (2003b). Signalling to and from tight junctions. *Nat Rev Mol Cell Biol*, Vol.4, No.3, (Mar), pp.225-236

Michaluk, P. & Kaczmarek, L. (2007). Matrix metalloproteinase-9 in glutamate-dependent adult brain function and dysfunction. *Cell Death and Differentiation*, Vol.14, No.7, (Jul), pp.1255-1258, ISSN 1350-9047

Mihaly, A. & Bozoky, B. (1984). Immunohistochemical localization of extravasated serum albumin in the hippocampus of human subjects with partial and generalized epilepsies and epileptiform convulsions. *Acta Neuropathol*, Vol.65, No.1, pp.25-34, ISSN 0001-6322

Miksys, S. & Tyndale, R.F. (2004). The unique regulation of brain cytochrome P450 2 (CYP2) family enzymes by drugs and genetics. *Drug Metabolism Reviews*, Vol.36, No.2, (May), pp.313-333, ISSN 0360-2532

Miller, D.S. et al. (2008). Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve central nervous system pharmacotherapy. *Pharmacological Reviews*, Vol.60, No.2, (Jun), pp.196-209, ISSN 1521-0081

Miller, D.S. et al. (1998). Protein kinase C regulation of p-glycoprotein-mediated xenobiotic secretion in renal proximal tubule. *American Journal of Physiology*, Vol.275, No.5 Pt 2, (Nov), pp.F785-795, ISSN 0002-9513

Minn, A. et al. (1991). Drug metabolizing enzymes in the brain and cerebral microvessels. *Brain Research Brain Research Reviews*, Vol.16, No.1, (Jan-Apr), pp.65-82

Mistry, P. et al. (2001). In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. *Cancer Research*, Vol.61, No.2, (Jan 15), pp.749-758, ISSN 0008-5472

Mukherjee, S.C. (2001). Epileptic and non-epileptic seizures. *Journal of the Indian Medical Association*, Vol.99, No.2, (Feb), pp.78-79, ISSN 0019-5847

Nag, S. (2003). Morphology and molecular properties of cellular components of normal cerebral vessels. *Methods Mol Med*, Vol.89, pp.3-36

Nagy, Z. et al. (1984). Fracture faces of cell junctions in cerebral endothelium during normal and hyperosmotic conditions. *Laboratory Investigation*, Vol.50, No.3, (Mar), pp.313-322

Narang, V.S. et al. (2008). Dexamethasone increases expression and activity of multidrug resistance transporters at the rat blood-brain barrier. *Am J Physiol Cell Physiol*, Vol.295, No.2, (Aug), pp.C440-450, ISSN 0363-6143

Nawa, A. et al. (2010). Inducible nitric oxide synthase-mediated decrease of intestinal P-glycoprotein expression under streptozotocin-induced diabetic conditions. *Life Sciences*, Vol.86, No.11-12, (Mar 13), pp.402-409, ISSN 1879-0631

Ndode-Ekane, X.E. et al. (2010). Vascular changes in epilepsy: functional consequences and association with network plasticity in pilocarpine-induced experimental epilepsy. *Neuroscience*, Vol.166, No.1, (Mar 10), pp.312-332, ISSN 1873-7544

Nemeroff, C.B. & Crisley, F.D. (1975). Monosodium L-glutamate-induced convulsions: temporary alteration in blood-brain barrier permeability to plasma proteins. *Environmental Physiology and Biochemistry*, Vol.5, No.6, pp.389-395, ISSN 0300-5429

Neuwelt, E.A. et al. (2011). Engaging neuroscience to advance translational research in brain barrier biology. *Nat Rev Neurosci*, Vol.12, No.3, (Mar), pp.169-182, ISSN 1471-0048

Nishijima, T. et al. (2010). Neuronal activity drives localized blood-brain-barrier transport of serum insulin-like growth factor-I into the CNS. *Neuron*, Vol.67, No.5, (Sep 9), pp.834-846, ISSN 1097-4199

Nishimura, M. et al. (2004). Tissue-specific mRNA expression profiles of human nuclear receptor subfamilies. *Drug Metab Pharmacokinet*, Vol.19, No.2, (Apr), pp.135-149, ISSN 1347-4367

Nitsch, C. & Hubauer, H. (1986). Distant blood-brain barrier opening in subfields of the rat hippocampus after intrastratial injections of kainic acid but not ibotenic acid. *Neuroscience Letters*, Vol.64, No.1, (Feb 14), pp.53-58, ISSN 0304-3940

Nitsch, C. & Klatzo, I. (1983). Regional patterns of blood-brain barrier breakdown during epileptiform seizures induced by various convulsive agents. *Journal of the Neurological Sciences*, Vol.59, No.3, (Jun), pp.305-322, ISSN 0022-510X

O'kane, R.L. & Hawkins, R.A. (2003). Na⁺-dependent transport of large neutral amino acids occurs at the abluminal membrane of the blood-brain barrier. *Am J Physiol Endocrinol Metab*, Vol.285, No.6, (Dec), pp.E1167-1173, ISSN 0193-1849

O'kane, R.L. et al. (1999). Na(+) -dependent glutamate transporters (EAAT1, EAAT2, and EAAT3) of the blood-brain barrier. A mechanism for glutamate removal. *Journal of Biological Chemistry*, Vol.274, No.45, (Nov 5), pp.31891-31895, ISSN 0021-9258

Oby, E. & Janigro, D. (2006). The blood-brain barrier and epilepsy. *Epilepsia*, Vol.47, No.11, (Nov), pp.1761-1774, ISSN 0013-9580

Oude Elferink, R.P. & Jansen, P.L. (1994). The role of the canalicular multispecific organic anion transporter in the disposal of endo- and xenobiotics. *Pharmacology and Therapeutics*, Vol.64, No.1, (Oct), pp.77-97, ISSN 0163-7258

Owen, A. et al. (2001). Carbamazepine is not a substrate for P-glycoprotein. *British Journal of Clinical Pharmacology*, Vol.51, No.4, (Apr), pp.345-349, ISSN 0306-5251

Oztas, B. & Kaya, M. (1991). The effect of acute hypertension on blood-brain barrier permeability to albumin during experimentally induced epileptic seizures. *Pharmacological Research*, Vol.23, No.1, (Jan), pp.41-46, ISSN 1043-6618

Oztas, B. & Sandalci, U. (1984). Reversibility of blood-brain barrier dysfunction in acute hypertension induced by angiotensin. *Experimental Neurology*, Vol.84, No.3, (Jun), pp.666-670, ISSN 0014-4886

Padou, V. et al. (1995). Changes in transport of [14C] alpha-aminoisobutyric acid across the blood-brain barrier during pentylenetetrazol-induced status epilepticus in the immature rat. *Epilepsy Research*, Vol.22, No.3, (Nov), pp.175-183, ISSN 0920-1211

Palade, G.E. (1961). Blood capillaries of the heart and other organs. *Circulation*, Vol.24, (Aug), pp.368-388, ISSN 0009-7322

Pardridge, W.M. (1991). Blood-brain barrier transport of glucose, free fatty acids, and ketone bodies. *Advances in Experimental Medicine and Biology*, Vol.291, pp.43-53, ISSN 0065-2598

Pardridge, W.M. (2003a). Blood-brain barrier drug targeting: the future of brain drug development. *Mol Interv*, Vol.3, No.2, (Mar), pp.90-105, 151, ISSN 1534-0384

Pardridge, W.M. (2003b). Blood-brain barrier genomics and the use of endogenous transporters to cause drug penetration into the brain. *Curr Opin Drug Discov Devel*, Vol.6, No.5, (Sep), pp.683-691, ISSN 1367-6733

Patel, V.A. et al. (2002). Regulation of MDR-1 (P-glycoprotein) by cyclooxygenase-2. *Journal of Biological Chemistry*, Vol.277, No.41, (Oct 11), pp.38915-38920, ISSN 0021-9258

Pekcec, A. et al. (2009). Targeting prostaglandin E2 EP1 receptors prevents seizure-associated P-glycoprotein up-regulation. *Journal of Pharmacology and Experimental Therapeutics*, Vol.330, No.3, (Sep), pp.939-947, ISSN 1521-0103

Pennock, G.D. et al. (1991). Systemic toxic effects associated with high-dose verapamil infusion and chemotherapy administration. *Journal of the National Cancer Institute*, Vol.83, No.2, (Jan 16), pp.105-110, ISSN 0027-8874

Petito, C.K. et al. (1977). Ultrastructural characteristics of the brain and blood-brain barrier in experimental seizures. *Brain Research*, Vol.127, No.2, (May 27), pp.251-267, ISSN 0006-8993

Poller, B. et al. (2010). Regulation of BCRP (ABCG2) and P-glycoprotein (ABCB1) by cytokines in a model of the human blood-brain barrier. *Cellular and Molecular Neurobiology*, Vol.30, No.1, (Jan), pp.63-70, ISSN 1573-6830

Potschka, H. et al. (2002). P-Glycoprotein-mediated efflux of phenobarbital, lamotrigine, and felbamate at the blood-brain barrier: evidence from microdialysis experiments in rats. *Neuroscience Letters*, Vol.327, No.3, (Jul 26), pp.173-176, ISSN 0304-3940

Potschka, H. & Loscher, W. (2001). In vivo evidence for P-glycoprotein-mediated transport of phenytoin at the blood-brain barrier of rats. *Epilepsia*, Vol.42, No.10, (Oct), pp.1231-1240, ISSN 0013-9580

Potschka, H. et al. (2004). Pharmacoresistance and expression of multidrug transporter P-glycoprotein in kindled rats. *Neuroreport*, Vol.15, No.10, (Jul 19), pp.1657-1661, ISSN 0959-4965

Ravindranath, V. et al. (1990). NADPH cytochrome P-450 reductase in rat, mouse and human brain. *Biochemical Pharmacology*, Vol.39, No.6, (Mar 15), pp.1013-1018, ISSN 0006-2952

Reese, T.S. & Karnovsky, M.J. (1967). Fine structural localization of a blood-brain barrier to exogenous peroxidase. *Journal of Cell Biology*, Vol.34, No.1, (Jul), pp.207-217

Rieder, C.R. et al. (2000). Human brain cytochrome P450 1B1: immunohistochemical localization in human temporal lobe and induction by dimethylbenz(a)anthracene in astrocytoma cell line (MOG-G-CCM). *Neuroscience Letters*, Vol.278, No.3, (Jan 14), pp.177-180, ISSN 0304-3940

Rigau, V. et al. (2007). Angiogenesis is associated with blood-brain barrier permeability in temporal lobe epilepsy. *Brain*, Vol.130, No.Pt 7, (Jul), pp.1942-1956, ISSN 1460-2156

Rigor, R.R. et al. (2010). Activation of PKC isoform beta(I) at the blood-brain barrier rapidly decreases P-glycoprotein activity and enhances drug delivery to the brain. *Journal of Cerebral Blood Flow and Metabolism*, Vol.30, No.7, (Jul), pp.1373-1383, ISSN 1559-7016

Rizzi, M. et al. (2002). Limbic seizures induce P-glycoprotein in rodent brain: functional implications for pharmacoresistance. *Journal of Neuroscience*, Vol.22, No.14, (Jul 15), pp.5833-5839, ISSN 1529-2401

Rodriguez-Baeza, A. et al. (2003). Morphological features in human cortical brain microvessels after head injury: a three-dimensional and immunocytochemical study. *Anat Rec A Discov Mol Cell Evol Biol*, Vol.273, No.1, (Jul), pp.583-593

Ronne-Engstrom, E. et al. (1992). Intracerebral microdialysis of extracellular amino acids in the human epileptic focus. *Journal of Cerebral Blood Flow and Metabolism*, Vol.12, No.5, (Sep), pp.873-876, ISSN 0271-678X

Salazar, A.M. et al. (1985). Epilepsy after penetrating head injury. I. Clinical correlates: a report of the Vietnam Head Injury Study. *Neurology*, Vol.35, No.10, (Oct), pp.1406-1414, ISSN 0028-3878

Schaefer, J.A. et al. (1975). Disturbance of the blood-brain barrier in electroshock-induced seizures. *Neurology*, Vol.25, pp.382

Schlichtiger, J. et al. (2010). Celecoxib treatment restores pharmacosensitivity in a rat model of pharmacoresistant epilepsy. *British Journal of Pharmacology*, Vol.160, No.5, (Jul), pp.1062-1071, ISSN 1476-5381

Seiffert, E. et al. (2004). Lasting blood-brain barrier disruption induces epileptic focus in the rat somatosensory cortex. *Journal of Neuroscience*, Vol.24, No.36, (Sep 8), pp.7829-7836, ISSN 1529-2401

Shang, W. et al. (2008). Expressions of glutathione S-transferase alpha, mu, and pi in brains of medically intractable epileptic patients. *BMC Neurosci*, Vol.9, pp.67, ISSN 1471-2202

Simpson, I.A. et al. (2007). Supply and demand in cerebral energy metabolism: the role of nutrient transporters. *Journal of Cerebral Blood Flow and Metabolism*, Vol.27, No.11, (Nov), pp.1766-1791, ISSN 0271-678X

Singh, A. et al. (2010). Expression of ABCG2 (BCRP) is regulated by Nrf2 in cancer cells that confers side population and chemoresistance phenotype. *Mol Cancer Ther*, Vol.9, No.8, (Aug), pp.2365-2376, ISSN 1538-8514

Sisodiya, S.M. et al. (2002). Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy. *Brain*, Vol.125, No.Pt 1, (Jan), pp.22-31, ISSN 0006-8950

Sisodiya, S.M. et al. (2003). Major vault protein, a marker of drug resistance, is upregulated in refractory epilepsy. *Epilepsia*, Vol.44, No.11, (Nov), pp.1388-1396, ISSN 0013-9580

Sisodiya, S.M. et al. (2006). Vascular colocalization of P-glycoprotein, multidrug-resistance associated protein 1, breast cancer resistance protein and major vault protein in human epileptogenic pathologies. *Neuropathology and Applied Neurobiology*, Vol.32, No.1, (Feb), pp.51-63, ISSN 0305-1846

Sokrab, T.E. et al. (1989). Endogenous serum albumin content in brain after short-lasting epileptic seizures. *Brain Research*, Vol.489, No.2, (Jun 12), pp.231-236, ISSN 0006-8993

Spatz, H. (1933). Die Bedeutung der vitalen Färbung für die Lehre vom Stoffaustausch zwischen dem Zentralnervensystem und dem übrigen Körper. *Archiv für Psychiatrie*, Vol.101, pp.267-358

Sperling, M.R. et al. (1999). Seizure control and mortality in epilepsy. *Annals of Neurology*, Vol.46, No.1, (Jul), pp.45-50, ISSN 0364-5134

Stamatovic, S.M. et al. (2008). Brain endothelial cell-cell junctions: how to "open" the blood brain barrier. *Curr Neuropharmacol*, Vol.6, No.3, (Sep), pp.179-192, ISSN 1570-159X

Stollberger, C. & Finsterer, J. (2003). Nonsteroidal anti-inflammatory drugs in patients with cardio- or cerebrovascular disorders. *Zeitschrift für Kardiologie*, Vol.92, No.9, (Sep), pp.721-729, ISSN 0300-5860

Strazielle, N. & Ghersi-Egea, J.F. (1999). Demonstration of a coupled metabolism-efflux process at the choroid plexus as a mechanism of brain protection toward xenobiotics. *Journal of Neuroscience*, Vol.19, No.15, (Aug 1), pp.6275-6289, ISSN 0270-6474

Su, T.Z. et al. (1995). Transport of gabapentin, a gamma-amino acid drug, by system l alpha-amino acid transporters: a comparative study in astrocytes, synaptosomes, and

CHO cells. *Journal of Neurochemistry*, Vol.64, No.5, (May), pp.2125-2131, ISSN 0022-3042

Sukhai, M. et al. (2001). Decreased expression of P-glycoprotein in interleukin-1beta and interleukin-6 treated rat hepatocytes. *Inflammation Research*, Vol.50, No.7, (Jul), pp.362-370, ISSN 1023-3830

Summers, M.A. et al. (2004). Use of verapamil as a potential P-glycoprotein inhibitor in a patient with refractory epilepsy. *Annals of Pharmacotherapy*, Vol.38, No.10, (Oct), pp.1631-1634, ISSN 1060-0280

Takara, K. et al. (2004). Carvedilol: a new candidate for reversal of MDR1/P-glycoprotein-mediated multidrug resistance. *Anti-Cancer Drugs*, Vol.15, No.4, (Apr), pp.303-309, ISSN 0959-4973

Tan, K.P. et al. (2010). Aryl hydrocarbon receptor is a transcriptional activator of the human breast cancer resistance protein (BCRP/ABCG2). *Molecular Pharmacology*, Vol.78, No.2, (Aug), pp.175-185, ISSN 1521-0111

Tayarani, I. et al. (1987). Evidence for an alanine, serine, and cysteine system of transport in isolated brain capillaries. *Journal of Cerebral Blood Flow and Metabolism*, Vol.7, No.5, (Oct), pp.585-591, ISSN 0271-678X

Thevenod, F. et al. (2000). Up-regulation of multidrug resistance P-glycoprotein via nuclear factor-kappaB activation protects kidney proximal tubule cells from cadmium- and reactive oxygen species-induced apoptosis. *Journal of Biological Chemistry*, Vol.275, No.3, (Jan 21), pp.1887-1896, ISSN 0021-9258

Tishler, D.M. et al. (1995). MDR1 gene expression in brain of patients with medically intractable epilepsy. *Epilepsia*, Vol.36, No.1, (Jan), pp.1-6, ISSN 0013-9580

Tomkins, O. et al. (2011). Blood-brain barrier breakdown following traumatic brain injury: a possible role in posttraumatic epilepsy. *Cardiovasc Psychiatry Neurol*, Vol.2011, pp.765923, ISSN 2090-0171

Tomkins, O. et al. (2008). Blood-brain barrier disruption in post-traumatic epilepsy. *Journal of Neurology, Neurosurgery and Psychiatry*, Vol.79, No.7, (Jul), pp.774-777, ISSN 1468-330X

Ueda, K. et al. (2007). Glutathione S-transferase M1 null genotype as a risk factor for carbamazepine-induced mild hepatotoxicity. *Pharmacogenomics*, Vol.8, No.5, (May), pp.435-442, ISSN 1744-8042

Ueda, Y. & Tsuru, N. (1995). Simultaneous monitoring of the seizure-related changes in extracellular glutamate and gamma-aminobutyric acid concentration in bilateral hippocampi following development of amygdaloid kindling. *Epilepsy Research*, Vol.20, No.3, (Mar), pp.213-219, ISSN 0920-1211

Van Vliet, E.A. et al. (2005). Expression of multidrug transporters MRP1, MRP2, and BCRP shortly after status epilepticus, during the latent period, and in chronic epileptic rats. *Epilepsia*, Vol.46, No.10, (Oct), pp.1569-1580, ISSN 0013-9580

Van Vliet, E.A. et al. (2006). Inhibition of the multidrug transporter P-glycoprotein improves seizure control in phenytoin-treated chronic epileptic rats. *Epilepsia*, Vol.47, No.4, (Apr), pp.672-680, ISSN 0013-9580

Van Vliet, E.A. et al. (2007). Region-specific overexpression of P-glycoprotein at the blood-brain barrier affects brain uptake of phenytoin in epileptic rats. *Journal of*

Pharmacology and Experimental Therapeutics, Vol.322, No.1, (Jul), pp.141-147, ISSN 0022-3565

Van Vliet, E.A. et al. (2010). COX-2 inhibition controls P-glycoprotein expression and promotes brain delivery of phenytoin in chronic epileptic rats. *Neuropharmacology*, Vol.58, No.2, (Feb), pp.404-412, ISSN 1873-7064

Vogelgesang, S. et al. (2004). Expression of multidrug transporters in dysembryoplastic neuroepithelial tumors causing intractable epilepsy. *Clinical Neuropathology*, Vol.23, No.5, (Sep-Oct), pp.223-231, ISSN 0722-5091

Volk, B. et al. (1988). First evidence of cytochrome P-450 induction in the mouse brain by phenytoin. *Neuroscience Letters*, Vol.84, No.2, (Jan 22), pp.219-224, ISSN 0304-3940

Volk, B. et al. (1995). Localization and characterization of cytochrome P450 in the brain. In vivo and in vitro investigations on phenytoin- and phenobarbital-inducible isoforms. *Toxicology Letters*, Vol.82-83, (Dec), pp.655-662, ISSN 0378-4274

Von Wedel-Parlow, M. et al. (2009). Regulation of major efflux transporters under inflammatory conditions at the blood-brain barrier in vitro. *Journal of Neurochemistry*, Vol.111, No.1, (Oct), pp.111-118, ISSN 1471-4159

Vorbrodt, A.W. & Dobrogowska, D.H. (2003). Molecular anatomy of intercellular junctions in brain endothelial and epithelial barriers: electron microscopist's view. *Brain Research Brain Research Reviews*, Vol.42, No.3, (Jun), pp.221-242

Walther, B. et al. (1986). Subcellular distribution of cytochrome P-450 in the brain. *Brain Research*, Vol.375, No.2, (Jun 11), pp.338-344, ISSN 0006-8993

Wang, X. et al. (2011). Aryl hydrocarbon receptor-mediated up-regulation of ATP-driven xenobiotic efflux transporters at the blood-brain barrier. *FASEB Journal*, Vol.25, No.2, (Feb), pp.644-652, ISSN 1530-6860

Wang, X. et al. (2010). Constitutive androstane receptor-mediated up-regulation of ATP-driven xenobiotic efflux transporters at the blood-brain barrier. *Molecular Pharmacology*, Vol.78, No.3, (Sep 1), pp.376-383, ISSN 1521-0111

Weiss, J. et al. (2003). Interaction of antiepileptic drugs with human P-glycoprotein in vitro. *Journal of Pharmacology and Experimental Therapeutics*, Vol.307, No.1, (Oct), pp.262-267, ISSN 0022-3565

Westergaard, E. (1980). Ultrastructural permeability properties of cerebral microvasculature under normal and experimental conditions after application of tracers. *Advances in Neurology*, Vol.28, pp.55-74, ISSN 0091-3952

Westergaard, E. et al. (1978). Increased permeability to horseradish peroxidase across cerebral vessels, evoked by electrically induced seizures in the rat. *Acta Neuropathol*, Vol.41, No.1, (Jan 19), pp.73-80, ISSN 0001-6322

Wolburg, H. & Lippoldt, A. (2002). Tight junctions of the blood-brain barrier: development, composition and regulation. *Vascul Pharmacol*, Vol.38, No.6, (Jun), pp.323-337, ISSN 0931-0155

Yu, C. et al. (2008). Neuroinflammation activates Mdr1b efflux transport through NFkappaB: promoter analysis in BBB endothelia. *Cellular Physiology and Biochemistry*, Vol.22, No.5-6, pp.745-756, ISSN 1421-9778

Zhu, H.J. & Liu, G.Q. (2004). Glutamate up-regulates P-glycoprotein expression in rat brain microvessel endothelial cells by an NMDA receptor-mediated mechanism. *Life Sciences*, Vol.75, No.11, (Jul 30), pp.1313-1322, ISSN 0024-3205

Zibell, G. et al. (2009). Prevention of seizure-induced up-regulation of endothelial P-glycoprotein by COX-2 inhibition. *Neuropharmacology*, Vol.Epub ahead of print, doi:10.1016/j.neuropharm.2009.01.009, pp., ISSN

Zlokovic, B.V. & Apuzzo, M.L. (1998). Strategies to circumvent vascular barriers of the central nervous system. *Neurosurgery*, Vol.43, No.4, (Oct), pp.877-878